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ABSTRACT
Amyloid diseases are characterized by the presence of highly insoluble
protein deposits in specific tissues or throughout the body. The amyloid protein
in Alzheimer's disease is the 1 protein, a ca. 4 kDa protein which derives from a
110-135 kDa precursor protein. The P protein is produced as an excreted protein
in cell culture, and has been detected in the CSF and blood of healthy
individuals. AD amyloid contains several variants of this protein, differing at
their N- and C-termini. The variants differing at the C-terminus have been
reported to have different properties: p1-39 and p1-40 are more soluble than
11-42 and P1-43. We have studied peptides derived from a bacterial protein
which are similar to the C-terminus of the p protein, and have shown that
amyloid fibril formation is a nucleation-dependent assembly process. The
kinetics are characterized by a lag phase, during which the peptide is apparently
soluble, followed by a growth phase, during which fibrils are rapidly formed.
Seeding with fragmented fibrils results in new fibril formation, bypassing the
rate-limiting nucleation step. Fibril formation requires highly specific
hydrophobic interactions, as demonstrated by the sequence specificity of
seeding. In peptides which model the C-terminus of the P protein, the longer
variants 26-43 and P26-42 form fibrils immediately while the shorter variants
126-40 and 126-39 have lag times of hours to days before fibril formation occurs.
Addition of fibrils derived from any of the P proteins results in seeding of the
slower nucleating variants. We have also studied the affect of the C-terminus on
the structure. Using 13C labeled peptides and solid-state NMR, we have shown
that P26-40 and 126-43 have a cis amide between Gly37 and Gly38. Using
isotope-edited FTIR, we show that there is considerable structural variation
between 126-40 and $26-43 in the vicinity of this cis amide. $26-43 appears
highly ordered while the slower nucleating $26-40 appears disordered. Finally
we show that hydrophobic effects in solution may stabilize the cis amide, and
this may play a critical role in the mechanism of amyloid formation.
Thesis Supervisor: Dr. Peter T. Lansbury, Jr.
Associate Professor of ChemistryTitle:
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Chapter 1
Alzheimer's Disease and the Amyloid P Protein
The human body deteriorates rapidly in old age, resulting in changes in
appearance and physical abilities. 1 Wrinkled skin, stiff joints, brittle bones, and
reduced lung function are all due to changes in connective tissue proteins, in
particular cross-linking of collagen. Most other organs deteriorate, resulting in
impaired function. In particular, the kidneys lose nephrons, resulting in a
decrease in the ability to remove waste products from the blood. The continual
presence of waste products results in the overload and weakening of the immune
system.1 Yet throughout such profound deterioration of the body, many
individuals are capable of maintaining a sharp, active mind. Winston Churchill,
for instance, was Prime Minister of Britain from age 65-80, during some of the
most politically difficult years of this century. Pablo Picasso maintained his
artistic productivity until his death at age 92.1 Other individuals may show signs
of senility (from the Latin senex: old man) in their 80's, yet as the word implies,
we have long considered a slight deterioration of the mind as a normal part of
late stages of the aging process. However, in certain individuals, the aging
process seems reversed. Starting as early as their fourth or fifth decade, patients
with Alzheimer's disease (AD) begin to lose their cognitive functions, including
memory, language use, perception, abstract thought, and the ability to solve
problems and make judgments. 2 Yet they maintain relatively healthy bodies. In
essence, they lose only those abilities which are characteristic of human existence,
the ability to think abstractly and to make judgments based on the memory of
past experiences.
The loss of memory is not always the most noticeable symptom of AD.
Alzheimer described his first patient: "The first noticeable symptom of illness ...
was suspiciousness of her husband .... believing that people were out to murder
her, [she] started to scream loudly. . . . At times she is totally delirious . . ."3,4
While memory and cognitive skills may initially deteriorate, patients often deny
or hide these problems from their family; the first signs of AD are often psychotic
symptoms such as withdrawal, explosiveness, delusions, and hallucinations,5
which derive from a loss of control over thoughts and actions. It is only later, as
cognitive abilities become seriously impaired, that awareness fades and patients
require constant care. The occurrence of AD increases with age, doubling every 5
years. Approximately one-third of individuals over the age of 85 have diagnosed
AD. 2 The prevalence of AD has increased in our society due to improvements in
sanitation and medicine which have led to a general aging of our population.1 In
1987, ~10% of our population was over 65,6 while -1% of our population had
AD. The estimated costs of caring for these persons was over $40 billion/year. 6
This amount will increase dramatically as we approach the 21st century.
Pathological features of AD
Although presenile dementia had been recognized since the mid 19th
century, Alzheimer took advantage of advances in cell staining to observe
pathological changes in brain sections upon autopsy. Upon silver staining
cortical slices, he noted extensive neuron death in the cerebral cortex. In
addition, he noted two features which are now considered the hallmarks of AD:
intracellular neurofibrillary tangles and extracellular neuritic plaques. Plaques
are dense deposits of protein and glycoprotein surrounded by clusters of
degenerating nerve terminals and the remnants of dead cells.2 Cerebrovascular
amyloid is usually found as sheaths which form around the blood capillaries of
the meninges, cortex, and hippocampus, often resulting in damage to the blood-
brain barrier. Neurofibrillary tangles are composed primarily of
hyperphosphorylated forms of the protein tau, which is a major component of
the cytoskeleton. They are also observed in other neurological disorders, and are
believed to be a general indication of cell death, rather than a cause of AD. 7
Granulovacuolar bodies, a type of inclusion body, are also found in certain
hippocampal neurons. 2 Finally, there is considerable atrophy of the cerebral
cortex which results in a loss of 10-15% of total brain weight relative to age-
matched controls. 2
The understanding of Alzheimer's disease has been hampered by the
inability to diagnose the disease until autopsy. The features of the disease noted
by Alzheimer require brain section and staining to observe plaques and tangles.
It is now known that AD causes ~55% of cases in a class of disorders known as
presenile dementia.2 However, there is some debate over whether AD is a single
disease, or a group of disorders which manifest similar symptoms and
pathological changes. 8 Systematic diagnosis now relies heavily on standard tests
of cognitive skills. The first of these was developed by Blessed, who was able to
show correlations between dementia and the extent of cortical cell death. 9 Those
patients who had no history of stroke showed a strong correlation between
mental-status scores and the number of neuritic plaques. 9 This was the first and
is still the strongest evidence regarding the cause of AD symptoms: dementia
seems to be caused by extensive cortical cell death, and in AD, this cell death is
accompanied by plaque formation.
Amyloid Plaques
Plaques are observed in silver-stained cortical tissue sections as 50-100 pm
diameter dark, spherical masses surrounded by dystrophic neurites. 7 The tissue
surrounding these plaques is characterized by dead neurons, primarily
cholinergic neurons, and by the presence of intracellular 10-20 ptm neurofibrillary
tangles. The composition of the plaques has remained ambiguous, and is
complicated by difficulties in separating plaques from the surrounding tissue
without losing weakly bound components. The plaque cores have recently been
successfully purified by centrifugation followed by fractionation of the pellet
using a fluorescence-activated cell sorting system. 10 11 The major inorganic
components include aluminum, iron, calcium, and silicon.12-14 The protein
components which have been identified include the P protein,
cc1-antichymotrypsin, 15 serum amyloid P, 16 heparan sulfate proteoglycan,
protease nexin-I, and cholinesterases, along with various unidentified trace
components.17 The primary organic component is the P protein, accounting for
>60% of plaque core protein.14
The P protein was first extracted from vascular plaques by Glenner and
Wong using 6 N guanidine HCl.18 They showed that this was a ca. 4 kDa protein
and they reported a partial N-terminal sequence. An identical sequence was
later identified in neuritic plaque cores, 19 and the sequence was extended to 40
residues in p protein derived from meningovascular amyloid.20 The plaque
protein from the neuritic plaques proved more difficult to solubilize or sequence.
This P protein is insoluble in 6 N guanidine HC1, but has been solubilized in
formic acid. One laboratory was able to sequence the first 24 residues, and
confirmed that the plaque core protein was the same sequence as the vascular
amyloid protein.19 However, sequencing proved difficult due to the presence of
Figure 1.1
Sequences of P proteins found in amyloid deposits.' 4
FRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVVIA
DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVVIA euriticFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVV
DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVV
DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVV
AEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVV vascula1
DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGV
AEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGV
heterogeneity at the N-terminus, possibly also including chemically modified N-
termini.7,21
Recently, two independent laboratories have characterized the contents of
the vascular and neuritic plaques using mass spectrometry and N-terminal
chemical sequencing. David Miller and coworkers along with loannis
Papayannopoulos of the MIT mass spectrometry facility carefully characterized
the components of cerbrovascular amyloid and amyloid plaque core proteins.' 4
They found that the neuritic plaques contained 25% protein by weight. Of this
protein, 90% was formic acid soluble, and 70% (by wt., -95% by mole fraction) of
the acid-soluble fraction was P protein. The neuritic plaques contained a
heterogeneous mixture of P proteins. (Figure 1.1) The N-terminus was
determined by chemical sequencing and was found heterogeneous, with
peptides beginning at each of the first 10 residues. The primary component
began at Phe-4. After chymotryptic digest, the C-terminal peptides were purified
and identified as a mixture of Val-40 and Ala-42; the relative amounts were not
ascertained. The cerebrovascular amyloid was less heterogeneous: the N-
terminus was a mixture of Asp-1 and Ala-2, while the C-terminus was a mixture
Figure 1.2
Diagram of the f Amyloid Precursor Protein.
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of Val-39 and Val-40. Another laboratory has reported similar results, 22 although
their study was not as meticulous with regard to the purification and
quantitation of the P proteins. In partially purified cerebral amyloid, they found
peptides with heterogeneity at the N-terminus, and C-termini which ended at
Val-39, Val-40 and Thr-43.
The Source of the P Protein
After Glenner reported a partial sequence for the vascular plaque, it was
assumed that the small amyloid protein must derive from a larger precursor, and
the race was on to clone and sequence the full length precursor. Several groups
identified the sequence for a 110-135 kDa protein termed the P amyloid precursor
protein (APP).23 27 (Figure 1.2) This protein is expressed in three forms through
differential mRNA splicing: a 695, 751, and 770 residue forms differing by two
small inserts. The 56 residue insert in the longer APPs corresponds to a known
protease inhibitor sequence. All three APPs have a long extracellular section,
which is N- and 0-glycosylated and tyrosyl-sulfated in human cell cultures. 7,21
Figure 1.3
Mutations in APP linked to amyloid disease.
--EVKMDAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVVIATVIVIT- -
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The P protein sequence begins at residue 597 (APP-695) in the extracellular
domain and extends into the predicted transmembrane region. The protein also
contains a short cytoplasmic tail which contains a signal sequence for endocytotic
degradation. The structure or function of the APP proteins are unknown,
although it has been suggested that the membrane-bound APP may have a role
in cell adhesion.21
Identification of the APP protein as the source of the P protein in plaques
led other researchers to probe whether some cases of AD could be explained by
mutations in the APP DNA sequence. The APP gene was found on the long arm
of chromosome 21. In Down's syndrome, three copies of chromosome 21 result
in an overproduction of APP; amyloid plaques are found in the brains of
deceased Down's syndrome patients even in early childhood.17 In addition,
genetic-linkage studies have shown that in some cases, early-onset AD could be
linked to genetic markers on chromosome 21.28 In 1990, it was discovered that a
rare disease, hereditary cerebral hemorrhage with amyloidosis, Dutch type, is
caused by a point mutation in the APP gene, substituting glutamine for glutamic
acid at position 693. This residue is at position 22 of the P protein from AD. 29
(Figure 1.3) Independently, several families were discovered with mutations in
APP which occur within the transmembrane sequence, but just outside of the P
protein sequence. These result in the rather conservative mutation of valine to
isoleucine, phenylalanine, or glycine. 30 Additional mutations have since been
discovered in the APP gene, summarized in Figure 3. Unfortunately, these
mutations account for less than 1 percent of all AD cases. Also, there is evidence
that other families may have mutations on other chromosomes which also
cosegregate with the disease, but are unrelated to the APP gene. However, the
genetic evidence supports the theory that the protein is causative in at least
some instances of Alzheimer's disease.
The sequence of APP suggests that the p protein is liberated by at least
two protease cleavages, one N-terminal to Asp-671 in the extracellular domain,
and one in the vicinity of Val-709 to Thr-713 located within the transmembrane
domain. (Figure 1.4) In certain cell lines, as much as 80% of APPs are degraded
nonspecifically via a lysosomal pathway. 23 However, -20% of APPs undergo
cleavage to release a soluble N-terminal domain (685-745 kDa) 31 while the C-
terminal domain undergoes endocytosis and is degraded in lysozomes. 7 (Figure
1.4, center pathway) The secretase which carries out this cleavage has been
shown to have little sequence specificity, but rather cleaves APP ~12-13 residues
outside the membrane, and seems to require a specific structure which was
disrupted by the presence of a proline mutant. 23,32 Cleavage by this protease
seems to be the dominant processing pathway for APP; this pathway leads to
truncated P proteins, which may also be amyloidogenic, although they have not
been detected in mature plaques.' 4 Two other pathways have been discovered in
cell culture which are believed to release the intact P protein. One cleavage event
generates C-terminal APP fragments which contain the entire P protein
sequence. 33-35 (Figure 1.4, cleavage I) These protein fragments were found
associated with lysosomes, and have the potential of generating the P protein
intracellularly. The corresponding soluble APP derivatives which stopped at
Met-596 (APP-695) were found in cell medium and CSF.36 Another cleavage
Figure 1.4
Processing of APP by the P secretase, proteinase I, and proteinase II pathways.
Numbers refer to residues in APP-695 for production of $1-42.
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event generates the C-terminus of the P protein in cell culture. (Figure 1.4,
cleavage II) Together with the first cleavage, this generates the intact P
protein. 37,38 The N-terminus was determined to be Leu-(-1) 38 or Asp-1 and Leu-
17.37 The precise C-terminus was not ascertained; the approximate molecular
weights were 4 and 3 kDa. Finally, the extracellular domain of APP has been
detected which apparently contains the intact P protein at its C-terminus. 39 This
finding indicates that the 3 protease events are independent of each other, and
639 695
there is no necessary proteolysis sequence which must be followed. All of the
possible cleavage products have been observed in cell culture. The processing
pathways are summarized in Figure 1.4.
The P Protein is Produced as a Normal Extracellular Protein
Detection of the P secretase products led to the assumption that this was
the "normal" processing pathway for APP.23 In the search for the "abnormal"
cleavage products, a surprising result was obtained. Using antibodies to
synthetic P1-40, the P protein was detected in both cell culture medium37,38,40 and
in biological fluids from both normal and AD patients. 38,40 Selkoe and
coworkers 37 transfected human kidney cells with APP-695, and detected 4 kDa
and 3 kDa proteins with P protein immunoreactivity. Radiosequencing revealed
the N-terminus was Asp-1 for the 4 kDa protein, and Val-18 for the 3 kDa
protein. The C-termini were not determined. Younkin and coworkers 38
transfected human leukemia cells with an 11.4 kDa C-terminal derivative of APP
and with APP-695. Both cell lines produced P protein in the cell medium.
Radiosequencing indicated that this P protein began at Asp-1; the C-terminus
was not determined. The amount of P protein was estimated to be 40% of the 10
kDa fragment derived from the P secretase cleavage. Since the secretase is
estimated to account for -20% of APP processing,23 this would indicate that the
production of the P protein may account for as much as 8% of APP processing.
CSF from 5 of 7 AD patients and 3 of 7 normal age-matched controls also
contained detectable amounts of f protein.38 The P protein was also detected in
biological fluids by Seubert and coworkers. 36 Using a monoclonal antibody
affinity column, they purified P protein from the CSF and blood plasma of
normal humans, dogs, guinea-pigs, and rats. They estimated the concentration
to be 1-5 ng/ml (0.2-1 nM). The major peak eluting from the affinity column was
identified by mass spectrometry as p1-40. However, several other proteins with
high affinity were not identified.
/ Protein Aggregate May Be Neurotoxic
While the presence of amyloid plaques in AD brains is an important
hallmark of the disease, any model for the progression of the disease must
account for cell death, since the observed symptoms of AD are caused by the
death or atrophy of cholinergic neurons in the cerebral cortex.41 Cell death seems
to be more pronounced in regions near plaques, but has been noted in tissue that
did not contain plaques. Perhaps the most controversial issue in AD research has
been the cause of neuronal death. Bruce Yankner found his work thrust under
the microscope of his peers when he demonstrated that synthetic P protein
caused neuronal death both in human neuronal cell culture and in rat brain. 42
Other researchers spent a great deal of time and money trying to reproduce
Yankner's results, many with little success. 43 Unfortunately, researchers used
different cell lines, different peptide sources, and also different solvent systems
for administration. One laboratory tested 7 peptide batches from the same and
different sources.44 They found high levels of toxicity in only 1 of 7 batches, but
could not detect differences in purity or identity based on HPLC, mass
spectrometry, or amino acid analysis. This indicates that small, undetectable
impurities have a major impact on the process which causes toxicity.
Confirmation of Yankner's results came from Cotman and Glabe, 45 who showed
that there is a correlation between the aggregation state of the P protein and its
neurotoxicity in cell culture. This aggregation-dependent toxicity could be
induced by aging peptide samples for 2-4 days at >10 jM peptide concentration.
These results suggest that aggregated f protein may cause cell death in the AD
brain.
Many other mechanisms have been proposed for cell death in AD,
including disruption of ion homeostasis, disruption of the cytoskeleton (tau), and
changes in membrane phospholipids, yet none have satisfied all of the
observations in AD.46 It has been recognized that the cell death in the AD brain
has the classic markers of a chronic inflammatory process.7 These include
activated microglia (macrophages), astrocytes expressing interleukin-1, and the
presence of a 1-antichymotrypsin.7 Also present in close association with
amyloid plaques are the complement proteins C1q and C4d, which are associated
with the immune system. Rogers, et al., 46 have shown that the P protein directly
activates the classic complement cellular toxicity pathway without mediation by
immunoglobulins. This pathway, through a series of binding and activation
reactions, results in the formation of the multisubunit membrane attack complex,
which lyses cell membranes in the immediate vicinity of the antigenic protein.
While it is not clear whether aggregation is required for this activation, in vitro
experiments were performed with 500-1500 pM stock solutions, suggesting that
this peptide may have been aggregated. In summary, the P protein appears to be
neurotoxic in an aggregation-dependent manner, and this neurotoxicity is
mediated by the classic complement immune response pathway.
The preceding pages have described a general theory for the molecular
pathology of Alzheimer's disease, beginning with the most basic observations
about the symptoms of the disease which were recorded 90 years ago, and
proceeding to a case for the direct involvement of P protein amyloid fibrils in the
disease process. Most of the understanding of the biology of plaque formation
has been unraveled in the last five years, during the course of the work described
in this thesis. Our understanding and interpretation of our own work has
evolved as we learned more about AD and protein assembly from other
researchers. This thesis will present our initial work on fibril formation by a
peptide derived from a bacterial protein; this demonstrated that amyloid fibril
formation was a nucleation-dependent process. It will then describe a few
examples of nucleation-dependent protein assembly processes, upon which a
general model for fibril formation can be based. Kinetic experiments with
peptide models derived from the C-terminus of the P protein provide some
additional insight into possible modes of in vivo amyloid formation. Finally,
structural studies have provided preliminary evidence upon which a speculatory
mechanism for amyloid formation can be based.
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Chapter 2
Amyloid Fibril Formation is a Nucleation-Dependent Assembly
Process
The presence of amyloid plaques is not unique to Alzheimer's disease. A
number of diseases are characterized by the presence of plaques in either a single
organ or throughout the body.1' 2 Very little is known about the detailed
mechanism of amyloid formation in any of these diseases. Amyloid plaques are
usually obtained upon autopsy and, due to their insolubility, provide very little
structural information, and virtually no information regarding the mechanism of
formation.3 This chapter describes efforts to unravel the mechanism of amyloid
fibril formation by hydrophobic peptides. For the purpose of this initial study,
we chose a peptide derived from a bacterial protein, the OsmB gene product
from E. coli.4,5 This peptide resembles the C-terminus of the P protein and is also
similar to silk sequences, which also form fibrillar structures. 6 After briefly
discussing the current understanding of amyloidosis, this chapter will present
evidence that amyloid fibril formation is a nucleation-dependent polymerization
process. As a nucleation-dependent process, it can be seeded by addition of fibril
fragments. In addition, fibril formation is a chemically-specific process, requiring
sequence-specific interactions between the peptide and the seed fibril. This type
of behavior will compared to two well-characterized protein assembly processes:
tubulin polymerization and sickle-cell hemoglobin polymerization. Finally,
based upon these examples, the general features, of a nucleation-dependent
mechanism for amyloid formation will be described, the assumptions inherent in
the model will be discussed, and the predicted rate curves will be compared to
the experimental results.
Amyloidosis
Amyloid Disease
Amyloid diseases are characterized by the presence of insoluble protein
deposits in the affected organs. There are more than thirty amyloid diseases,
representing a broad range of conditions, both pathologically and biochemically.1
The common feature shared by all of these diseases is the presence of amyloid
plaques surrounded by damaged tissue. Rudolph Virchow, upon noting that the
plaques stained with a sulfuric acid/iodine protocol, concluded that the plaques
must consist of cellulose, thus he coined the term amyloid.7 It was soon proven
that the plaques were proteinaceous, but 130 years later, the term amyloid is still
in use. The plaques are highly insoluble and resistant to denaturants, and thus
are not amenable to biochemical analysis. In the absence of data to the contrary,
it was often assumed that the amyloid found in different diseases was the same
protein, thus early papers often refer to human amyloid filaments, without citing
the protein, disease, or organ source of the preparations. 8 In 1970, Glenner and
coworkers successfully purified 9 and sequenced10 the amyloid protein from a
fatal systemic amyloidosis. This protein proved to be a fragment of the
immunoglobulin light chain. Since then, fifteen amyloid proteins have been
identified, summarized in Table 2.1.2 Based upon the work of Glenner and
others, three criteria have come into common usage as definition of amyloid:
insoluble proteinaceous material that (1) stains with the dye Congo red, (2) has a
fibrillar morphology as viewed by electron microscopy, with 10 nm wide,
Table 2.1
Proteins involved in human amyloid diseases and the apparent cause of amyloid
formation. P: proteolysis; M: mutation; C: conformational change. Adapted
from ref. 2, 12.
Distribution Precursor Cause Amyloid Protein
Systemic Immunoglobulin (23 kD) P Immunoglobulin (5-23 kD)
Systemic Apolipoprotein-SAA (12 kD) P Apo-SAA (8 kD)
Systemic Apolipoprotein-AI (26 kD) M, P Apo-AI (9-11 kD)
Systemic Transthyretin (14 kD) M, P, C ATTR (5-14 kD)
Pancreas Pro-IAPP (9 kD) P IAPP (4kD)
Thyroid Calcitonin (14 kD) P Calcitonin (6 kD)
Muscular P-2-microglobulin (12 kD) C P-2-microglobulin (12 kD)
Brain PAPP (110-135 kD) P, M P protein (4 kD)
Brain Cystatin C (13 kD) M Cystatin C (12 kD)
Brain PrP cellular (30-35 kD) C Prion (30-35 kD)
unbranched, twisted fibrils, and (3) shows a characteristic cross-P X-ray fiber
diffraction pattern. These criteria, especially the first two, are essential for
distinguishing amyloid from other fibrillar material in tissue sections. However,
these criteria may not be an indication of any common structure,11 this is
discussed in more detail below.
In each amyloid disease, the precursor protein has proven to be a soluble
or membrane-bound protein which undergoes an alteration resulting in an
insoluble variant. In many cases, this alteration is a familial genetic mutation
which significantly changes the processing or solubility properties of the
precursor, resulting in plaque formation and eventual amyloidosis. For example,
in hereditary cerebral hemorrhage with amyloidosis-Dutch type, a substitution of
glutamine for glutamic acid at residue 22 of the P protein results in formation of
vascular amyloid. With short peptides derived from this sequence, the mutated
form has been shown to aggregate more rapidly.13 In hereditary cystatin C
amyloid angiopathy, the protease inhibitor cystatin C is mutated resulting in a
glutamine 68 to leucine substitution. This mutation is believed to result in
impaired secretion and intracellular accumulation of cystatin C. 2 Amyloidosis in
this case may be analogous to inclusion body formation (discussed below).
Proteolysis can liberate a small fragment of an otherwise soluble or membrane-
bound protein; the fragment may be much less soluble than its precursor,
particularly if it is derived from a hydrophobic sequence within the protein. This
may be responsible for amyloid formation in AD as was discussed in chapter 1.
Finally, a conformational change can result in aggregation of an otherwise
soluble protein. The protein transthyretin has been found in both native and
proteolyzed states in plaques. Colon and Kelly have shown that the full length
protein is soluble; however, the protein forms amyloid fibrils when it is partially
denatured at acidic pH, similar to conditions encountered within the lysozome.14
A similar type of aggregation-induced conformational change may be
responsible for the conversion of cellular prion protein (PrP) to infectious
amyloid PrP in the prion diseases. 15,16
Mechanism of In Vivo Amyloid Formation.
Very little is known about the details of in vivo amyloidogenesis. Since
amyloidosis is a human disease occurring in sensitive organs which are not
amenable to biopsy, amyloid plaques are usually only observed upon autopsy.
Glenner has studied the structure of systemic amyloid derived from the
immunoglobulin light chain. Using X-ray diffraction he studied non-oriented
and mechanically oriented amyloid fibril preparations, and observed bands
corresponding to 4.75 A and 9.8 A.8 These correspond to the interstrand and
intersheet distances in an antiparallel f-sheet. After orienting the fibrils, he
showed that the P strands are perpendicular to the fibril axis. On the basis of this
evidence, he suggested that the structure is similar to the cross- structure
described by Pauling and Corey 17 and observed in silk from Chrysopa.18
However, X-ray diffraction does not require that the entire protein be in the
cross-n structure, since random, non-repeating structures will not contribute to
the diffraction pattern. Glenner also studied these plaques using infrared
spectroscopy of the amide I band. 19 He studied dried plaques in KBr pellets and
as films from 50% formic acid solution. The spectra showed vibrational bands at
~1630 cm-1 which were 40-60% of the total absorption intensity. These are
typically assigned as antiparallel p-sheet.20 He obtained similar spectra when
proteolytic fragments of immunoglobulin proteins were dissolved in 50% formic
acid and dried as films. This observation suggests that amyloid formation from
immunoglobulin light chain may represent denaturation and aggregation at
acidic (lysosomal) pH of otherwise soluble protein fragments. In this respect,
amyloid formation may have much in common with in vitro protein aggregation.
The structural and possibly mechanistic link between amyloid formation
and in vitro protein aggregation has been reviewed by Wetzel.21 He suggests that
the aggregation of proteins during in vitro refolding experiments, the formation
of bacterial inclusion bodies, and the formation of mammalian amyloid deposits
may all follow similar mechanistic pathways. The current understanding of
protein refolding is that a protein first collapses to a molten globule state,
possessing secondary structural elements, but little tertiary structure. The
molten globule exposes more hydrophobic surface area than the folded protein.
If this exposed hydrophobic surface is ordered, then proteins may begin to
aggregate in an ordered array, resulting in a stable aggregate. Often, this type of
aggregation requires partial denaturation, which exposes some hydrophobic
surfaces but allows the protein to maintain a defined structure. For example,
tryptophanase aggregates into a highly insoluble aggregate at 3 M urea, but
when an 8 M urea solution (completely denatured and soluble) is rapidly diluted
into buffer, refolding procedes with very little aggregation. 22 This type of
denaturation-dependent aggregation was observed for at least two amyloid
proteins. Glenner noted that the FTIR spectrum of immunoglobulin amyloid
could be reproduced by dissolving the folded immunoglobulin protein in formic
acid and then slowly dialyzing into native buffer. 19 Colon and Kelly observed
that transthyretin aggregated upon partial denaturation in acidic conditions,
resulting in amyloid fibrils.14 Some forms of amyloidosis may be similar to
inclusion body formation in bacteria. In most cases, inclusion body formation
occurs when a protein is overexpressed at concentrations which are higher than
its solubility. 21 This may be similar to cystatin C amyloid, in which a mutation
causes decreased secretion and therefore, intracellular sequestration of the
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protein above its solubility. 2 Studies of protein aggregation have led to several
conclusions with consequences for amyloid formation. First, point mutations can
cause dramatic changes in aggregation properties by altering the balance of
partially folded intermediates. 23 Second, certain proteins act in vivo to prevent
protein aggregation, particularly the chaperonins (hsp60 and hsp70). These bind
weakly to partially folded proteins, preventing aggregation until either secretion
or complete folding is accomplished. 21 Finally, protein aggregation can be
reduced by addition of small molecule inhibitors. These may act in the same
manner as chaperonins. 24
In summary, amyloid formation generally results from the localized
concentration of an insoluble protein or protein fragment. This can be the result
of a mutation which results in increased production, altered processing,
sequestration, or decreased solubility of the amyloid protein. In other cases,
abnormal proteolytic processing may liberate a fragment which has different
solubility properties than the original protein. In other cases, amyloid may result
from partial denaturation of the amyloid protein in the absence of chaperonins,
resulting in aggregation of folding intermediates. In any case, amyloid plaques
share properties and structural features with in vitro protein aggregates,
suggesting that the in vitro study of amyloid protein folding and aggregation
may lead to a better understanding of the disease process.
Fibril Formation by Peptides Derived from the E. coli OsmB Protein
Sequence Similarities Exist in Amyloid Proteins
Amyloid diseases are caused by a wide range of proteins. These differ in
sequence and in origin.1 We wondered whether some of these proteins and
possibly other unidentified proteins might share a sequence homology that
contributes to their insolubility. Experiments in our laboratory had shown that
while many peptides derived from the P protein of AD could form fibrils, only
peptides derived from the C-terminus shared similar solubility properties with
full length P protein. 25 In addition, Kurt Halverson showed that a peptide
derived from residues 34-42 of the P protein had an unusual structure centered
around a cis-amide between Gly-37 and Gly-38. 12,26 He noted that residues 25-40
contained an unusual sequence periodicity: glycine was repeated at every fourth
residue. (Figure 2.2) The presence of abnormally high levels of glycine and
serine was also noted in immunoglobulin derived systemic amyloid.27 This is
reminiscent of silk protein from Bombyx mon, which contains the consensus
sequence (GAGS)n6 and of the egg stalk protein of Chrysopa flava, which contain
the repeat (GSAS)n. 28 It has been proposed that glycine plays a unique role in
cross-0 fibrils, allowing the protein to form a bend and zig-zag back and forth
across the fibril.29 It is not clear why glycine would be required for this role; its
flexibility may be important in maintaining a tight turn and optimal packing.
The conformational flexibility of glycine may allow the peptide chain to adopt
conformations not normally populated in globular proteins. 30 In particular, p-
sheets in globular proteins are normally twisted by as much as 15-30' per
strand,31 while the twist periodicity observed in fibrils suggests that P sheets in
fibrils twist less than 1' per strand (this assumes that fibrils are really composed
of extended P sheets, this may not always be the case).12 Twisting of P sheets is
normally due to the steric interaction of i and i+2 side-chains, 31 and the presence
of glycine may allow sheets to compensate and remain flat.30
Figure 2.2
Sequence of the C-terminus of the P protein showing the GXXX repeat, along
with the scrapie prion protein and two regions from the OsmB protein.
P protein (29-42): . G..AIIGLMVGGVVIA-CO2H
Prion Protein (96-111): ... AGAVVGGLGGYMLGSA...
OsmB Protein (14-25): .. .GAGAGALGGAVL ...
OsmB Protein (28-44): ... GSTLGTLGGAAVGVIG...
We developed a set of criteria in order to search for proteins homologous
to the C-terminus of the P protein. (see experimental section for details) We
insisted on at least 3 contiguous repeats of the GXXX repeat observed in residues
29-40 of the P protein. We reasoned that the X-residues would be located in the
core of the fibril and would therefore be uncharged and would not be proline,
which disrupts P structure. Thus, we limited X to G, A, V, I, L, F, W, Y, T, S, or
M. Eighty sequences were obtained upon searching the sequence database.
Sequences containing polyglycine and long GXGX repeats (silk proteins) were
eliminated. We also reasoned that residues which are common in the -sheets
found in globular proteins would be likely to populate the 1-sheet structures
which are characteristic of many amyloids.30 The remaining sequences were
screened for those that were relatively hydrophobic (hydropathy 2 1.4),32 and
contained residues often found in 1-sheets but rarely in c-helices in globular
proteins(Pp-Pa 0.17).33 Twenty-seven sequences survived including the P
amyloid protein (res. 29-40), the scrapie prion protein (res. 96-111), and the E. coli
OsmB protein (res. 14-25 and res. 28-44) (Figure 2.2).
The E. coli OsmB protein contains two similar sequence repeats,
comprising ca. 70% of the 49 residue protein.4 OsmB is a periplasmic outer
membrane-associated lipoprotein, which is upregulated in response to osmotic
Figure 2.3
Sequence of the peptide derived from OsmB(28-44) and two controls, OsmG3
and OsmA.
OsmB(28-44): AcNH-GSTLGTLGGAAVGGVIG-CONH2
OsmG3: AcNH-GSTGLTGLAGAVGVIGG-CONH2
OsmA: AcNH-GSTLATLGAAAVAGVIG-CONH2
stress. Its function is unknown, but it has been suggested that it plays a role in
reinforcing the outer membrane, preventing cell death during sudden osmotic
changes. 4 We synthesized a peptide corresponding to residues 28 through 44 of
the OsmB protein (Figure 2.2 & 2.3) in order to investigate the hypothesis that
this sequence motif drives amyloid formation. Our preliminary findings were
that the peptide (OsmB(28-44)) was initially soluble in water (~1 mg/ml), but
formed a solid when the solution was stirred or allowed to stand for several
days. This solid showed fibrillar morphology by electron microscopy. (Figure
2.3A) Since our initial search was based on the hypothesis that the glycine repeat
was important in fibril formation, we synthesized two control peptides to test
this hypothesis. OsmG3 had the same amino acid content as OsmB(28-44), but
the sequence was minimally rearranged to generate a sequence which had
glycine at every third residue. (Figure 2.3) OsmA was a "mutated" form of
OsmB(28-44) in which three of the glycines were replaced with alanine.
OsmB Derived Peptides Form Amyloid Fibrils
Metastable supersaturated solutions of each peptide could be prepared in
water. These solutions were stable for hours to days, depending upon the degree
of supersaturation. Agitation of these solutions by stirring or sonication caused
aggregation to occur with little or no delay. The degree of aggregation could be
followed by measuring the turbidity of the solutions, and generally approached
an equilibrium within 1-2 hr. The aggregates were studied by electron
microscopy and Fourier-transform infrared spectroscopy, and tested for Congo
red staining and birefringence.
As viewed by electron microscopy, (Figure 2.4) the morphology of the
peptide fibrils varied slightly. In general, amyloid fibrils are expected to form
long unbranched fibrils, 50-100 A in diameter, with a periodic twist, and should
associate in parallel bundles. OsmB(28-44) formed twisted fibrils 100-150 A in
diameter, with a twist periodicity of 1300 ± 100 A. These fibrils aggregated in
two distinct forms, depending on peptide concentration. In more dilute samples
(<500 pM), two fibrils twisted around each other in a helical manner with a
periodicity of 1800 A. In concentrated samples, the fibrils tended to clump into
ribbon-like structures containing 20-30 fibrils, with each ribbon about 200 x 1000
A in cross section and several thousand nanometers long; these ribbons also
clumped strongly together. OsmG3 formed fibrils which were similar to those
from OsmB(28-44) with respect to width and twist periodicity, however the
OsmG3 fibrils tended to wind together in larger fibrils containing between 2-5
smaller fibrils. OsmA formed straight rods, also about 100 A in diameter, with
no observable twist. These clumped together in a parallel manner, but with no
distinguishable higher-level order.
The aggregates of each peptide were also tested for Congo red binding
and birefringence. All of the peptide aggregates bound Congo red, resulting in
reddish-pink films. After staining, both OsmB(28-44) and OsmA exhibited
yellow-green birefringence, however, stained OsmG3 was not birefringent. As
was mentioned above, Congo red binding and birefringence, along with
morphological examination of the fibrils, is used to histochemically define
Figure 2.4
Electron micrographs of (OB) OsmB(28-44) left formed at 425 PM, right formed at
1 mM; (OG) OsmG3; (OA) OsmA, both formed at 425 pM. Bar = 1000 A.
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amyloid in tissue. Amyloid fibrils should be unbranched, 50-100 A in diameter,
form dense parallel bundles, and when stained with Congo red, should show
green birefringence under a polarized light microscope. This definition is useful
in order to histochemically separate amyloid from the confusing mass of other
proteins and tissue fragments present in tissue sections. However, these criteria
may not guarantee that all amyloids share common structural features, and they
may exclude other materials which are structurally similar but fail to meet one of
these criteria.11 Fibril morphology is certainly indicative of some underlying
sequence-dependent interactions. However, the factors which limit the diameter
or length of amyloid fibrils are not understood. A similar phenomenon results in
the limitation of crystal growth under certain conditions, and while this has been
characterized experimentally, it has not been explained on theoretical grounds.34
Likewise, while Congo red binding and birefringence was one of the earliest
histochemical markers of amyloid, the mode of dye binding is not understood.
Cooper has argued that the dye binds specifically to P structure by intercalating
into the hydrophobic space between sheets. 35 This holds the dye molecules
planar, resulting in birefringent absorbance. While this may be one mode of
binding, unpublished results from our laboratory indicate that charge may also
be important but not essential, 36,37 and that the extent of binding is not related to
the amount of n-structure present. Until more is known, it must be concluded
that while Congophilicity may be important as a histological tool, it makes little
sense as a definition of a structural protein class. 11 Thus, while each of the
peptides described above do not completely meet the histological criteria for
amyloid, this may be a problem with the criteria; the peptides may still share
structural features with in vivo amyloid.
FTIR of Peptide Fibrils
Peptide amyloid fibrils derived from OsmB contained P-sheet structure as
shown by the vibrational absorption bands at -1630 cm-1 and 1695 cm-1 (Figure
2.5).20 In fact, the intensity of this band suggests that these peptides contain
significantly more s-structure than amyloid fibrils derived from in vivo sources. 19
The absorption band at ~1665 cm- 1 may indicate the presence of a 1-turn, but
other authors have shown that the assignment of bands in this region is not
straightforward. 38 Beyond the presence of highly couple structures which may
be p structure, it is very difficult to determine any other information from these
infrared spectra. As Kurt Halverson in our lab showed, even the observation of
antiparallel p-structure in the infrared spectrum is not straightforward. 12 The
observation of a shifted band at 1625-30 cm-1 is due to transition dipole coupling
between aligned carbonyls which are close in space, and while 1-structure is the
most common structure which can lead to vibrational coupling, it is certainly not
the only structure.20 With respect to the OsmB peptides, while the general
positions of the bands are similar for all three peptides, there are slight
differences in the band shape, which may indicate significant differences at the
molecular level.11
Circular Dichroism of Peptide Solutions
Circular dichroism was used to assess the amount of structure formed by
each peptide in aqueous solution. The CD spectra in buffer (100 mM NaCl, 10
mM phosphate, pH 7.4) at 100 pM were consistent with a random-coil
conformation.39,40 (Figure 2.6) The three peptides were indistinguishable under
these conditions. The temperature could be raised or lowered (5 and 50 'C)
without significantly changing the spectrum, reinforcing the interpretation of
these spectra as unstructured. Since OsmB is normally expressed during periods
Figure 2.5
FTIR of peptide fibrils. (OB) OsmB(28-44); (OA) OsmA; (OG) OsmG3. Fibrils
were spread as a thin film on a CaF2 plate and dried in vacuo.
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Figure 2.6
Circular Dichroism of OsmB(28-44) at 100 pM. (+) 0.1 M KF; (o) 1.0 M KF; (1) 90%
TFE; (x) 30% HFIP; (A) 5% SDS
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of high salt exposure, 4 we measured the spectra in high salt buffer (1 M KF). The
spectra were indistinguishable from those observed in low salt. In distilled
water, this unstructured spectrum was maintained over a broad range of
concentrations (10-1000 tM). Further concentration of each peptide resulted in
formation of insoluble material. This transition occurred at - 1 mM for OsmB(28-
44), 1.2 mM for OsmG3, and 0.5 mM for OsmA. Changes in the CD spectra were
not observed at any concentration, indicating that significant levels of structured,
soluble aggregates were not formed. Upon aggregation, the CD signal decreased
dramatically, however, the shape of the spectrum was similar to that observed
for soluble peptide. The aggregate appeared to'not contribute to the CD
spectrum. The solid obtained upon concentration showed FTIR spectra similar to
40
those observed above, (Figure 2.5) dominated by a band at 1630 cm-1, possibly
indicative of P structure.
The CD spectra of each peptide was also recorded in varying amounts of
trifluoroethanol, hexafluoroisopropanol, and sodium dodecyl sulfate. In
trifluoroethanol, each peptide gradually assumed a helical conformation,
reaching a maximum at 90% TFE/H 20. (OsmB(28-44) is shown in Figure 2.6)
This corresponded to 30-40% helicity as estimated by the method of Morrisett. 40
Similar results were obtained in hexafluoroisopropanol, except that this
cosolvent proved to be a stronger helix inducer, resulting in maximum helicity at
30% HFIP. (Figure 2.6) In this solvent system, OsmB(28-44) was 48% helical,
OsmG3 was 41% helical, and OsmA was 77% helical. (Figure 2.7) The increased
helicity in OsmA is consistent with the relative helix propensities of Gly and
Ala.41,42 Addition of more than 30% HFIP resulted in a gradual loss of helicity.
In anhydrous HFIP, the peptide appeared to take on P structure, indicated by
positive ellipticity at 200 nm. In sodium dodecyl sulfate (5% w/v), the peptides
also assumed helical structure, similar to what is often observed for hydrophobic
transmembrane sequences.43 Glycine is considered a helix-destabilizing residue
based upon data from globular proteins; however, it is common in
transmembrane helices, and appears to be less destabilizing under such
conditions. 44 In fact, the unusually high glycine content of membrane-spanning
sequences may play a functional role,45 and may account for the high glycine
content of the C-terminus of the P protein.
Solubilities of OsmB Derived Peptides are Similar
Supersaturated solutions of each peptide in water and in buffer were
stirred for several days. Solid aggregate formed within hours, however, the
solution was stirred to ensure complete aggregation. The suspensions were
Figure 2.7
Circular Dichroism of (+) OsmB(28-44); (o) OsmG3; (1) OsmA; at 100 pM in 30%
HFIP/H20.
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centrifuged and filtered through 0.2 pm filters. The concentration of soluble
peptide was determined for each peptide and is summarized in Table 2.2. OsmA
was the least soluble, -3-4 times less soluble than OsmB(28-44), while OsmG3
was only slightly more soluble than OsmB(28-44). The lower solubility of OsmA
can be explained in terms of both the increased hydrophobicity and decreased
entropy of the soluble monomer. Unexpectedly, the peptide solubilities are only
slightly lower in buffered salt solution (100 mM NaCl) than in purified water. If
the low solubility of the these peptides is primarily due to hydrophobic
interactions, one would expect that salt would increase these effects, resulting in
decreased solubility, especially in the case of OsmA. For example, the P proteins
are believed to be much more soluble in pure water than in salt solutions.4
Table 2.2
Solubility of OsmB derived peptides (kM).
peptide H20 buffer
OsmB 50 42
OsmG3 83 60
OsmA 13 15
Time-Dependent Aggregation of Peptide Solutions
Supersaturated peptide solutions could be prepared by gentle dissolution
of HFIP-derived peptide films, followed by filtration to remove undissolved
material. These films contain a high proportion of unstructured peptide, as
indicated by FTIR, and were more easily dissolved than lyophilized peptide. The
concentration of these supersaturated solutions could be determined by a
standard protein assay, after which the solutions were diluted to the same
concentration. Peptide solutions in water could be further supersaturated by the
addition of a small aliquot of a concentrated salt solution. The final salt
conditions (100 mM NaCl, 10 mM phosphate) and pH (7.4) were close to
physiological. The final peptide concentrations were 250-500 pM, which is ~10-
fold higher than the equilibrium solubilities measured under these conditions.
The resulting peptide solutions were allowed to equilibrate with minimal
disturbance. The turbidity of each solution was monitored at 400 nm after evenly
suspending any aggregates present. Turbidity has been used previously to
monitor aggregation,47 and is proportional to the mass of the aggregate in ideal
dilute suspensions of thin rods.48 OsmA initially appeared to be soluble, but
aggregated after several hours, resulting in an increase in the turbidity of the
solution (Figure 2.8). OsmB(28-44) and OsmG3 showed no aggregation for
Figure 2.8
Aggregation of peptides at 425 pM in buffer, as indicated by the turbidity of the
solutions. (1) OsmB; (s) OsmA; (n) OsmG3.
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several days either by visual inspection or measured turbidity. After this delay,
the peptide began to aggregate, forming visible particles which were detected by
a rise in the measured turbidity. The aggregation process reached an apparent
equilibrium after two weeks. The experimental procedures used are fraught with
difficulties, which result in limited reproducibility. These difficulties are similar
to those observed in protein crystallization 49 (impurities, sample manipulation,
etc.), and are primarily a consequence of the mechanism of assembly. This is
discussed in greater depth in the experimental section of this chapter.
This kinetic behavior, known as nucleation-dependent polymerization,
has been observed for the aggregation of glucagon5 0 and sickle-cell
hemoglobin,47 as well as for many normal protein assembly processes.51 The
most striking characteristic of this type of aggregation is the observation of a
delay time (or lag time), during which it appears that the peptide is soluble.
However, during this time, trace amounts of dimers, trimers, etc. are forming.
These small aggregates may be formed in such low concentrations that they are
undetectable by available experimental methods. The CD spectrum of OsmB(28-
44) was recorded at various times during the lag phase. The spectra were
identical until aggregation occurred, at which point the CD signal decreased but
the shape of the curve was similar. The prenucleation oligomers are highly
unstable, and most fall apart before they can add more monomer. Eventually,
larger aggregates are formed which are more stable, the result is that association
equilibria become favorable, resulting in rapid and thermodynamically favorable
growth. The growing aggregate inevitably uses up the available monomer, and
the system approaches a thermodynamic equilibrium; the concentration of
monomer approaches the thermodynamic solubility. This type of mechanism
has been explored in great detail for several protein systems; examples are
described in a later section.
Seeding of Supersaturated Peptide Solutions
The rate-limiting step which gives rise to the lag period is formation of a
structured nucleus upon which fibrils can grow. If this step can be bypassed,
immediate aggregation should occur. This is similar to protein crystallization,
where slow formation of an ordered nucleus can be bypassed by addition of a
small seed crystal, to which monomer can readily add and form a larger crystal. 34
By analogy to crystallization experiments, we generated seed fibrils by taking
previously formed fibrils and sonicating for 15 min to fragment the fibrils and
expose fresh growth surfaces. Suspensions of these fibrils (5 mole %, 12 nmol in
50 p1) were used to nucleate fibril growth from supersaturated solutions (250
nmol in 950 jtl) of each peptide (Figure 2.9). If an OsmB(28-44) solution was
seeded with OsmB(28-44) fibrils, growth occurred rapidly with t1/ 2 - 300 sec.
However, if an OsmB(28-44) solution was seeded with OsmG3 or OsmA fibrils,
the absorbance did not change over 30 min, indicating no fibril growth. Similar
results were observed for both OsmG3 (t1/ 2 - 200 sec) and OsmA (tl 2 - 75 sec)
solutions (Figure 2.9). None of the peptides show any aggregation over this short
time span without seeding. The concentration of soluble peptide remaining after
30 min was ~150 pM for each peptide seeded with its own fibrils, although fibril
growth had apparently stopped. Fibrils from OsmB(28-44) were sonicated for a
longer period(~90 min) and added to a supersaturated solution of OsmB(28-44).
The rate of fibril growth was similar, but the concentration of soluble peptide
remaining after growth had stopped was -90 pM, indicating that the extent of
fibril growth is limited by the degree of fragmentation of the seed fibril
suspension.
The observation of spontaneous fibril growth upon addition of seed fibrils
confirms that nucleus formation is rate-limiting. This seeding effect was found to
be sensitive to peptide sequence. While immediate growth was observed if
OsmB(28-44) fibrils were added to a supersaturated OsmB(28-44) solution,
addition of OsmG3 or OsmA fibrils resulted in no growth. (Figure 2.9) The same
result was observed for supersaturated OsmG3 and OsmA solutions: the
aggregation of each peptide could only be nucleated by addition of its own
fibrils. If aggregation of these peptides was due to non-specific hydrophobic
clustering, then virtually any hydrophobic peptide would have resulted in
growth of fibrils. The observed sequence specificity confirms observations from
FTIR and electron microscopy that the fibrils from each peptide have slightly
different structure. Fibril nucleation requires specific intermolecular
Figure 2.9
Seeding of Fibril Growth. Previously aggregated peptide (12.5
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hydrophobic interactions; that is, the seed must provide a template whose
structure is available to the incoming monomeric peptide.
The seeding experiments also suggest a rather unexpected result: the
growth of fibrils is limited to a finite length. When a seeded solution of
OsmB(28-44) reached an apparent equilibrium, the concentration of soluble
peptide was 150 pM, which is ~4x the thermodynamic solubility. If the seed
fibrils are sonicated for a longer period of time, resulting in increased
fragmentation, the observed turbidity after seeding was higher, and the amount
of soluble peptide remaining was 90 pM, now only ~2x the thermodynamic
solubility. If this suspension was then stirred, the solubility was reached within
two days. Furthermore, the rate of seeded growth (Figure 2.9, t1/ 2 - 300 sec) is
much faster than the rate of unseeded growth (Figure 2.8, t1/ 2 - td - 50 hr). Taken
together, these results suggest that each fibril, once seeded or nucleated, rapidly
grows to a limited length. Further consumption of monomer must require new
nucleation or seeding events. This type of behavior has been observed for
protein crystallization.9,34 The physical cause of this phenomenon is not known.
Kam has observed that lysozyme crystals are surrounded by a layer of buffer
which is depleted in protein, despite an abundance of protein in the bulk
solution.34 The crystal surface appears to repel the monomer after a certain size
limit is reached. The cessation of fibril growth may be due to a similar effect,
however it is not apparent how the end of a growing fibril can have any physical
knowledge of the length of a fibril which is several thousand nanometers long.
Summary
The peptide derived from the OsmB protein and two sequence analogs
form amyloid fibrils, which are slightly different as visualized by electron
microscopy. These stain with Congo red and contain P structure as indicated by
infrared spectroscopy. Peptide solutions contain no structure in aqueous buffers,
although helical structures can be induced with nonpolar cosolvents. These
unstructured aqueous solutions aggregate in a time-dependent manner. The
observed kinetics demonstrate a lag phase followed by a growth phase. The lag
phase can be circumvented by the addition of seed fibrils derived from the same
peptide. Seed fibrils derived from other peptides could not seed fibril formation.
This suggests that amyloid formation follows nucleation-dependent kinetics and
that specific intermolecular interactions are involved in the nucleation and
growth of amyloid fibrils.
Protein Self-Assembly Processes
The assembly of proteins into ordered structures is important in a number
of biological systems. 51,52 Multimeric proteins must be assembled from
separately synthesized subunits, often requiring highly specific pathways devoid
of certain intermediates. Viral and bacteriophage coats are assembled from
identical subunits which are often self-organized into three dimensional
structures, such as icosahedral spheres, into which nucleic acids insert. Tubulin
can polymerize to spontaneously form microtubules in vitro, but this
polymerization is tightly controlled in vivo by associated proteins, allowing
complete control of the cellular architecture. These assembly processes share
many common features. In each case, formation of small multimers is
disfavored, due to the entropic loss resulting from decreased rotational and
translational freedom. Initially, the limited intermolecular contacts do not
outweigh this loss of entropy, 53 and as a result, small multimers are present in
very low concentration, are unstable, and easily disintegrate. At some critical
size, the multimer becomes more stable due to increased intermolecular
interactions, and the polymer begins to grow spontaneously. This critical size is
referred to as the nucleus. I will refer to this type of nucleation mechanism as a
thermodynamically-limited mechanism. The thermodynamic source of
nucleation-dependent kinetics is easily visualized in the case of tubulin
polymerization, this will be discussed initially. Another factor which can
contribute to nucleation dependence is the slow growth of the nucleus due to
poor forward rate constants, this will be referred to as a kinetically-limited
mechanism. Mutant hemoglobin polymerization is described best by a variation
of this type of mechanism, and will serve to illustrate the importance of
nucleation-dependent assembly in human disease. A general scheme for
amyloid formation may require a combination of both the thermodynamically-
and kinetically-limited mechanisms.
Tubulin Polymerization - Thermodynamically-Limited Nucleation
Tubulin is the primary component of microtubules, helical polymers
which are the structural "girders" which provide cells with their unique shapes,
and which hold organelles in specific positions within the cell. 54 In vivo
polymerization is a tightly controlled process, requiring centrosome proteins,
which "seed" polymerization, and microtubule associated proteins (MAPs) and
GTP, which "glue" the resulting polymer together, preventing dissolution of
microtubules a low protein concentrations. 54 Relative to the in vivo scenario, the
assembly of tubules from purified tubulin in vitro is a simple process, requiring
only high concentrations of tubulin. The in vitro polymerization of tubulin
provides a unique opportunity to study both nucleation and growth in a
nucleation-dependent helical polymerization. Tubulin is a heterodimer of two 50
kD subunits; this large size allows direct visualization of small oligomers by
electron microscopy. This has been the primary tool for investigating the tubulin
nucleation mechanism.
A structural source for the nucleation-dependent mechanism can be
visualized in the simplified helical polymerization depicted in Figure 2.10A. This
mechanism holds that a linear aggregation process leads to formation of a partial
loop. Each protein makes only a single contact with its neighbor, this is not
enough to outweigh the high entropic cost of monomer binding,53 thus each
prenucleation step is characterized by a small Kn. When the loop is closed, each
additional monomer can now make contact with two neighbors; these contacts
are now sufficient to outweigh the entropic costs, and growth is rapid. This
mechanism, though aesthetically appealing, has been replaced in the literature by
a two-dimensional sheet nucleation model, as depicted in Figure 2.10B.55,56 In
this mechanism, the tubulin dimer initially nucleates and grows as a double
strand. Lateral nucleation of new strands coupled with rapid strand growth
increases the number of strands, until thirteen strands are laterally associated, at
which point the sheet closes into a tube. Linear growth occurs through addition
of dimers to the ends of strands. The curves predicted by this model are
compared to experimental data in Figure 2.10C (concentrations are from
turbidity measurements). The concentration-dependence observed in this data
corresponds to a nucleus size of 7 tubulin dimers. While the general shape of the
curves can be reproduced, the fit is better in the growth region rather than in the
nucleation region of the curve, suggesting that assumptions used to derive the
nucleation equations below may not be valid. This is discussed in more detail in
a later section.
The kinetic analysis which produces these curve fits can be described in
three relatively simple components.56 ,5 7 This analysis is based on the steady-
Figure 2.10
Proposed mechanisms for nucleation of microtubules. (A) Linear aggregation
followed by loop closure. (B) Sheet assembly followed by tube closure. (C)
Experimental data and theoretical curves predicted by model in B.
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state assumption; that is, the concentration of all intermediates is assumed to
have rapidly (before the first data measurement) reached an equilibrium value
which is negligible compared to the monomer and the aggregate concentrations.
This requires that the forward and reverse rates are initially rapid. In this case,
nucleation-dependence is the result of very small prenucleation equilibria, which
results in a low equilibrium concentration of nucleus. In this
thermodynamically-limited model, nucleation of two-filament sheets results
from rapid and reversible step-wise addition of tubulin to small oligomers:
M+M M2
M2 + M M3
M3 + M M4
kf
Mn-1 + M Mn Kn = (kf /kr)n-
(Eq. 2.1) kr
Where kf and kr are the forward an reverse rates of each individual step, and Kn
is the overall equilibrium for nucleus formation, which is the product of the
individual equilibria. If n is the number of monomers in the critical nucleus, then
the rate of appearance of stable two-stranded sheets with n+1 monomers is:
dCn+/dt = kf Co Cn - kr Cn+1
(Eq. 2.2) = (Co kf - kr) Kn (CO)n
where Co is the monomer concentration. This rather simple equation derives
from the assumption that all prenucleation steps are identical (identical kf and kr)
and that the concentration of n-mers and (n+1)-mers is approximately equal, that
is, that Cn = Cn,1 = Kn (Co)p. This assumption in particular may not be valid,
since nucleation dependence suggests that the prenucleation equilibria are poor;
thus Cn+1 << Cn. The concentration dependence of the lag time is based on
equation 2.2:
(Eq. 2.3) 1/td = K (Co)n
Due to the shape of the curves obtained (Figure 2.10C), the lag time is usually
defined as the tenth time: the time at which the measured quantity (turbidity) has
reached 10% of its final equilibrium value. This equation allows easy calculation
of the nucleus size from concentration-dependent curves like those in shown
Figure 2.10C. The second component of tubulin polymerization is lateral growth,
which requires a secondary nucleation event followed by rapid growth of the
new filament. This requires a formula of the type derived for nucleation above
(Eq. 2.2), with a summation of all sheets from two to thirteen strands in width.
(equations not shown) The final component of tubulin polymerization is
filament growth. This follows exponential growth kinetics:
(Eq. 2.4) dCi/dt = i(kf Ci CO - kr C)
Erickson and Voter introduce the factor i as a correction to this growth rate which
limits the growth of incomplete sheets. 56 This simplified kinetic approach, based
on the assumption that all prenucleation steps are identical and all
postnucleation steps are identical, provides a rather close fit to the data (Figure
2.10C), particularly in the growth phase. The disparity in the nucleation phase
suggests that the system may not have reached a steady state yet, that is, the
nucleation may be partially kinetically-limited. Also, the simplifying
assumptions may not be entirely valid, particularly the assumption that Kn is
close to one and is not a function of aggregate size. Theoretical consideration of
protein cluster formation in solution predicts that Kn is a function of n,
exponentially approaching a limiting value of Kg = (1 /solubility) as n approaches
infinity. 49 Even the simple equations described above cannot be solved
explicitly, and the curves in Figure 2.10C were generated by repeated numerical
integration with different values of kf, kr and n.
Hemoglobin S Polymerization - Kinetically-Limited Polymerization
Hemoglobin S is the result of a single point mutation at position 6 of the p
subunit of human hemoglobin A, resulting in the substitution of valine for
glutamate. 58 The structure of the folded protein remains largely unchanged, and
its activity with respect to oxygen affinity also appears unchanged. 47 In the
deoxygenated (venous) form of the protein, the glutamate normally appears on
the surface of the protein, and its substitution by valine results in a small
hydrophobic patch on the exterior of the protein, exposed to the solvent. The
protein is present in very high concentrations within the red-blood cell, (-320
mg/ml, 5 mM) and coupled with the high symmetry of the tetrameric protein,
this solvent-exposed hydrophobic patch results in self-assembly of an ordered
aggregate. The large size of the monomer allows visualization by electron
microscopy, this has resulted in a detailed description of the polymerization
mechanism based on the observed structure of the protein fibers. (Figure 2.11A)
Kinetic studies have allowed calculation of the nucleus size, and have
demonstrated that a complete description requires a rather complex kinetic
analysis. 47
Figure 2.11
Proposed mechanism for nucleation of hemoglobin S. (A) Slow homogeneous
nucleation followed by rapid heterogeneous nucleation on preexisting fibrils. (B)
Typical experimental data at two temperatures as measured by turbidity.
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Comparison of the progress curves of hemoglobin S polymerization
(Figure 2.11B) with those for tubulin polymerization (Figure 2.10C) points to two
major differences. First, tubulin polymerization is initially slow, but even at very
short time points, growth occurs and aggregate is present. Hemoglobin
polymerization is characterized by the complete absence of aggregate during the
lag phase for aggregation. This is an indication that hemoglobin nucleation does
not occur through a steady-state production of nuclei, but is a kinetically-limited
nucleation process. Second, hemoglobin polymerization approaches equilibrium
much faster than tubulin polymerization. This requires a unique autocatalytic
mechanism, initially derived from observations in electron microscopy.
An analysis of the kinetics of hemoglobin S polymerization initially
requires a nucleation description identical to that described for tubulin:
M +M M2
M2 + M M3
M3 + M M4
kf
Mn.1 + M Mn Kn = (kf /kr)n~1
(Eq. 2.5) kr
However, at this point, instead of deriving the steady-state rate laws, we assume
that the approach to the steady state is rate-limiting. We can describe the rate of
each step:
(Eq. 2.6) dM 2 /dt = kfM 2 - krM 2
(Eq. 2.7) dMi / dt = kf M Mi - kr Mi
However,.calculation of the concentration of nuclei at any time would require the
solution of n coupled equations of this form. However, for short times
(t<<(1/k)n-1), the reverse rate can be ignored, and the concentration of any i-mer
can be described by the equation:59
(Eq. 2.8) Mi = Mi (kf t)i-1 / (i-1)!
By comparison of this curve with an explicit solution of the rate laws, Hofrichter
has shown that this equation is valid for the first 10% of the rate curve. 59 After
initial production of nuclei, the system follows steady-state kinetics and the
growth is described by the equation:
kf
Ci + C Ci+1
dp/dt kf 77 CCi
(Eq. 2.9) 7i+1
The activity coefficient of each species, y, must be included due to the high
concentration of the protein solution. In addition, the reverse rate is assumed to
be negligible. The concentration of homogeneous nuclei at steady state is given
by:
(Eq. 2.10) Cn = (y C)n Kn / yn
However, the fibril formation rate predicted by this nucleus concentration is not
high enough to account for the rapid approach to equilibrium observed at the top
of each curve. This is accounted for by the self-catalytic heterogeneous
nucleation mechanism depicted in Figure 2.11A. Prenuclei are stabilized by
attaching to the surface of a preexisting fibril. The concentration of nuclei formed
by this mechanism is described by:
(Eq. 2.11) Cn = K'n Kn $ (Co - C) (y C)n
Where K'n represents the equilibrium constant for n-mers in solution versus n-
mers attached to another fibril, and $ is a factor which accounts for the limited
number of sites available for specific attachment. Combining all of the steady-
state equations (Eq. 2.9, 2.10, 2.11) together:
(Eq. 2.12) dp/dt = kf Ki (yC)i+l / gi+1 + kf K'j Kj $ (CO - C) (yC)j+1
While a description of the mechanism of hemoglobin S polymerization is
interesting from a scientific viewpoint, its medical importance in the treatment of
the disease is not readily apparent. Eaton and Hofrichter have presented the case
that the mathematical mechanism may suggest therapies for the disease.4 7 The
observation of a pre-steady-state phase during which polymer production is
negligible suggests that if the system can be encouraged to remain in this phase,
then polymer will not form in the short trip through the veinal-capillary
system.47 The length of the pre-steady-state delay is predicted by equation 2.8 to
be:
(Eq. 2.13) 1 / td = X Cn
In practice, they substituted the supersaturation ratio S = (C(/solubility) instead
of the concentration above:
(Eq. 2.14) 1 / td = X Sn
This is valid when comparing delay times at two concentrations of the same
protein, since the solubility cancels when the ratio (S1/S 2)n is taken. Thus it
doesn't matter whether one discusses a system in terms of concentration or
supersaturation, the value of n obtained is the same. The nth order delay time
affect predicts that a slight decrease in hemoglobin concentration within red-
blood cells would result in a significant increase in delay time. Thus, treatments
which could cause slight swelling of blood cells would result in decreased
polymerization. Hofrichter, et al., also note that studies have demonstrated the
chemical specificity of the polymerization process.47 Mixtures of hemoglobin S
with hemoglobin A or hemoglobins from other species result in increased total
solubility, and presumably, decreased polymerization rates. In the future,
introduction of hemoglobin A via gene therapy may prove to be a viable long
term cure.
General Mechanism for Nucleation-Dependent Amyloid Formation.
The kinetic curves obtained for amyloid formation share features with
both tubulin and hemoglobin polymerization. Figure 2.12 compares the
experimental data for OsmB with curves based on hemoglobin and tubulin
polymerization. Like hemoglobin polymerization (Figure 2.12A), growth is
preceded by a long delay time; however, the growth is not nearly as rapid as in
hemoglobin, due to the absence of self-catalytic mechanisms in amyloid
formation. Like tubulin polymerization, aggregate accumulates at a slow rate
Figure 2.12
Aggregation of OsmB(28-44) (o, 425 ptM) compared to (A) hemoglobin model
and (B) tubulin model. (s) Best fit to early growth. (0) Affect of doubling kf. (x)
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during the delay time. (Figure 2.12B) However, the model which describes
tubulin polymerization (thermodynamically-limited mechanism) cannot alone
account for the observed rate curves: according to this model, the long delay
times observed should lead to much slower growth than is observed due to the
required low concentration of nuclei (small Kn). It seems that a combination of
these two models may be able to account for the observed curves. While nucleus
formation is initially rate-limiting (small kf), the later growth phase reaches
steady-state conditions, and is therefore thermodynamically limited (small Kn).
All mechanisms involving aggregation processes must initially involve
successive bimolecular associations:
M +M - M2
M2 + M - M3
M3 + M - -M 4
kf
(Eq 2.4)Mn + M .r Mn Kn = kf/kr
(Eq. 2.14) kr
The complete solution of the time-dependence of aggregation would require the
numerical integration of the corresponding rate equations from n=2 to n=-106:
(Eq. 2.15) dMn / dt = kf M Mn. 1 - kr Mn
This would be an imposing task, but would be possible with a powerful
computer. However, at this point we should explore the limitations of fitting
nucleation dependent curves. The nucleation-dependent rate curve is essentially
an exponential growth curve delayed by a lag time. Using the hemoglobin
62
model, Figure 2.12A also shows the affect of changing the lag time while
maintaining the same growth rate, and maintaining the same lag time while
doubling the growth rate. There are two degrees of freedom in the nucleation-
dependent curve, the delay time and the growth rate. Any model which hopes to
fit this data must require only two independent variables, which can
independently affect the lag time and the growth rate. This is the case for the
hemoglobin S model. In the case of tubulin polymerization, the simplified model
presented by Voter, et al.,56 contains two independent variables, kf and Kn;
however, these affect the lag time and growth rates in an identical manner.
(Figure 2.12B)
As shown in Figure 2.12, the hemoglobin model seems to model the
general shape of the experimental rate curves. However, our experimental
results demonstrate that a self-catalytic mechanism, as is proposed for
hemoglobin, is not at work in amyloid fibril formation. In particular, since
seeding results in only limited fibril formation, the presence of fibrils must not
catalyze nucleation of new fibrils. The fibril formation curves might be best
described by a combination of the hemoglobin and the tubulin models: initially,
the formation of n-mers is rate-limiting, while during the growth phase, the
system reaches a steady-state, and the equilibrium concentration of nuclei is rate-
limiting. The nucleus concentration at short time (during the lag phase) is
described by the equation derived by Eaton and Hofrichter for pre-steady-state
hemoglobin polymerization (Eq. 2.8):
(Eq. 2.16) Mn init = Mn (kf t)n-1 / (n-i)!
Note that this equation predicts that the delay timeis inversely proportional to
the monomer concentration to the nth power.
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(Eq. 2.17) 1 / td = K Mn
The value of n can be derived from this relationship. The pre-steady-state
approximation (Eq. 2.16) is valid until the predicted Mn is about 10% of the
steady-state equilibrium value for Mn:59
(Eq. 2.18) Mn ss = (Kn)n-1 Mn
This is the concentration of the nucleus at long time points, after nucleus
production has reached a steady state. The transition between the values for the
concentration of the nucleus predicted by these two equations (Eq. 2.16 & 2.18)
would normally require the numerical solution of the set of n rate equations (Eq.
2.15). However, if one assumes that the steady-state is approached relatively
quickly after initial nucleus production, then an approximate solution requires
only a rapid and smooth transition. A quick and dirty approach is to use the
following mathematical trick:
(Eq. 2.19) X(t) = Mn SS(t) / (Mn SS(t) + 10 Mn init(t))
(Eq. 2.20) Mn(t) = X Mn init(t) + (1-X) Mn SS(t)
When the pre-steady-state nucleus concentration is predicted to be less than 10%
of the steady-state concentration, then X is close to one, and Mn(t) is the
concentration of nuclei predicted by the initial rate equation (Eq. 2.16). The
converse is true at long t, when Mn init greatly exceeds 10% of Mn ss, X
approaches 0, Mn(t) approaches Mn ss, (Eq. 2.18) and the transition curve is sharp
and sigmoidal.
Once an approximate value for the concentration of nuclei at each time t is
derived, deriving the rate of aggregation is straightforward. First, it is assumed
that nuclei are converted into fibrils according to the rate kf:
(Eq. 2.21) d[fibril] / dt = kf Mn M
Finally, the growth of fibrils occurs through stepwise addition of monomers to
existing fibrils.
(Eq. 2.22) dMagg / dt = kf [fibril] M - kr [fibril]
Each step results in a reduction in the amount of free monomer, this is taken into
account in the subsequent calculation. The values which can be measured
directly are the initial monomer concentration, the final monomer concentration
(the solubility = kr/kf), and the nucleus size n. These equations contain three
independent variables which cannot be measured directly, kf for growth, kf for
nucleation, and the prenucleation equilibria, Kn. As discussed above, fitting the
data requires at most two independent variables. The simplifying assumption
which is made in the case of tubulin polymerization is that kf is constant for all
nucleation and growth steps. This leaves kf and Kn as independent variables.
This set of equations cannot be solved explicitly. However, the equations
can be entered into a spreadsheet, and the rate curve calculated to obtain an
approximate fit to the data. In Figure 2.13A, the model derived above is used to
fit the data depicted in Figure 2.8 for the unstirred aggregation of the OsmB-
derived peptides. The scatter in the experimental data allow some variation in
the fit, the parameters listed below are typical (for n=10):
Table 2.3
Kinetic parameters from curve fit depicted in Figure 2.13A
parameter OsmA OsmB/OsmG3
kf (M-1 sec-1) 0.35 0.018
km (sec-1) 7.6 x 10-5 9.5 x 10-6
krg (sec-1) 3.5 x 10-6 7.2 x 10-7
Kn (M-1) 1800 1900
The forward rate constants predicted by the model are slow, since diffusion-
limited reactions can approach 108 M- 1 sec- 1. This suggests that very few
collisions result in formation of an aggregate, most dissociate before a stable
complex is formed. This may argue for a two-step aggregation model, in which a
collision initially generates an unstable complex, which then undergoes a slow
intramolecular (conformational?) change, generating a more stable dimer.
M +M . - M*M - M2
Further support for this idea comes from analysis of the Kn, which determines
the steady-state nucleus concentration. These values are high; in fact, Kn = 1900
predicts that at 425 tM, the concentration of n-mer is ~80% of the concentration
of (n-1)-mer. In this model, the system is only slightly nucleation-dependent.
Such a large value for Kn is necessary to provide enough nuclei to account for
rapid growth after such long delay times. It is possible that n is much larger than
10 (modeled here); this would result in smaller values for Kn and kf. However,
as the table below and the fits in Figure 2.13B show, the values for Kn and kf are
not terribly sensitive to n.
Figure 2.13
(A) Aggregation of (A) OsmB(28-44); (q) OsmG3; and (o) OsmA, all at 425 gM,
concentrations calculated from turbidity data in Figure 2.8. Curve fits generated
as described in the text. (B) Curve fits at different values of n as described in text.
(0) n=5, (A) n=10, (x) n=15.
A.
0 200000 400000 600000 500000 1000000
time (sec)
B.
0
-10i0
0 20000 0M
time (sec)
Table 2.4
Sensitivity of Kn and kf to n. Curve fits are depicted in Figure 2.13B.
Kn kf
n=5 1900 0.007
n=10 1900 0.018
n=15 2050 0.029
A number of assumptions must be made in order to simplify an infinite
set of rate equations to a few manageable equations. The validity of some of
these assumptions should be examined.
forward rate constants: In order to reduce the number of independent variables, kf
is assumed to be the same for each step in the aggregation process. The forward
rate can be described as the product of the collision rate and the fraction of
collisions which lead to a stable complex. The collision rate should depend
primarily on the diffusion rate of the species involved. The diffusion rate of a
molecule is a function of the size of the molecule, however, since there is always
a vast excess of monomer relative to large aggregates, the diffusion contribution
to kf will be independent of aggregate size for monomer adding to n-mer. The
fraction of molecules which form stable complexes is related to the fit between
the structure of the monomer and the structure of the surface of the aggregate. In
fact, prenuclei may resemble "molten globule" protein folding intermediates,
since each molecule can maintain some degree of flexibility. The aggregate may
be more structured, this may increase the fraction of productive collisions, which
would increase kf.
nucleation: The model described above assumes that nucleation is initially
entirely rate-limiting. The formation of stable oligomers from initially unstable
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collisions may be responsible for this effect. However, the model predicts that
during the delay time, no aggregate is observed. Experimentally, small amounts
of aggregate are observed during the delay time. This might be explained by a
two-step collision model:
M
M + M - M*M .- M2 M 2*M
M
M*M*M ' M*M*M*M
Normally, aggregation procedes along the horizontal route, where the rate-
limiting step is formation of a stable complex from an unstable complex. Some
unstable complexes may add a monomer before they can dissociate or stabilize.
This would result in a small amount of aggregate bypassing the rate-limiting
steps, and forming during the lag phase. Another assumption is that all
prenucleation equilibria are identical (Kn is constant). In fact, Kam, et al., have
shown that Kn should be a function of n in unstructured nuclei. 34
growth: The model described assumes that during the growth phase, new fibrils
are produced by homogeneous nucleation only. We have eliminated the
possibility of a heterogeneous self-catalytic mechanism for nucleation on the
basis of seeding experiments. However, the model does not take into account the
increased fibril concentration due to occasional fragmentation of pre-existing
fibrils. If a small amount of aggregate is produced during the lag phase, this
would normally consume very little total monomer. However, if agitation or
thermal motions cause significant fracturing of the fibrils, then this will increase
the concentration of fibrils above what is predicted by homogeneous nucleation
alone, resulting in shortened lag times and more rapid growth.
A general kinetic model has been developed which combines aspects of
the tubulin and the hemoglobin cases. This model invokes pre-steady-state
initial rates to model the lag period, and steady-state kinetics to model the
growth period. Transition between these two models is accomplished via a
sigmoidal weighting function. This model is capable of producing curves which
fit the data. However, close examination of the kinetic data suggests a more
complex mechanism may be involved and the basic assumptions involved in the
model may be incorrect. A more complex model might be developed based on
the two-step collision model described above for prenucleation equilibria. This
model would result in the production of a small amount of aggregate continually
via a steady-state pathway involving unstructured, unstable oligomers, while the
majority of aggregate would be produced via a rate-limited pathway involving
structured oligomers. This model would also require a number of assumptions
in order to fit the data, and the complete development is beyond the scope of this
thesis.
Experimental
Materials.
The Rink amide methylbenzhydrylamine resin (substitution 0.6 mmol/g)
was obtained from Novabiochem. Fmoc-amino acids were obtained from
Advanced ChemTech. BOP reagent was obtained from Richelieu Biotech-
nologies. DIEA was obtained from Aldrich Chemical and distilled from
ninhydrin under reduced pressure. The BCA protein assay kit was obtained
from Pierce Chemical. Millex-GV 0.22 ptm filters were obtained from Millipore.
Protein Sequence Search.
The CAS Online protein sequence database was searched for proteins
which contained a repeating GXXX motif. At least 3 repeats (12 residues) were
required. The nonglycine residues were allowed to be virtually any uncharged
residue (G, A, V, I, L, F, W, Y, T, S or M). Proline was not allowed since it
disrupts j-sheet structure. 33  Eighty sequences were found. Sequences
containing polyglycine and long GXGX repeats (silk proteins) were eliminated.
The remaining sequences were screened for those that were relatively
hydrophobic (hydropathy 1.4)32 and contained residues often found in p-sheets
but rarely in a-helices in globular proteins(Pp-Pa 0.17).33 Twenty-seven
sequences survived including the p amyloid protein (res. 29-40), the scrapie prion
protein (res. 96-111), and the E. coli OsmB protein (res. 14-25 and res. 28-44).
Peptide Synthesis, Purification, and Characterization.
Peptides were synthesized manually on the Rink amide resin using commercially
available Fmoc-amino acids. The side-chains of serine and threonine were
protected as the t-butyl ethers. Fmoc-peptide-resin was deprotected with 50%
piperidine/DMF for 15 min. Coupling was achieved with 3 equiv. amino acid, 3
equiv. BOP and 6 equiv. DIEA in DMF for 1 hr. Couplings were monitored by
the Kaiser test.60 After coupling and deprotection of the final residue, the N-
terminus was acetylated with acetic anhydride and DIEA (10 equiv. each in
dichloromethane, 4 hr). The resin-bound peptides were cleaved and deprotected
with neat trifluoroacetic acid (30 min, 230). Since modifiable amino acids were
not present, scavengers were avoided in the deprotection. The resin was filtered
and washed with TFA and CH 2Cl 2. The combined filtrates were concentrated
and peptide was precipitated by adding dropwise to cold diethyl ether (100 ml).
The precipitates were collected by centrifugation, washed with additional ether,
and dried.
The crude solid was dissolved in hexafluoroisopropanol and purified by
reverse phase HPLC under isocratic conditions on a C4 semipreparative column
(YMC, 2.0 x 25 cm) using (H20 + 0.1% TFA) and (acetonitrile + 0.1% TFA) as
eluents. The collected fractions were concentrated in vacuo and lyophilized to
yield the peptide as a white solid. The purity of each peptide was confirmed by
reverse phase HPLC under isocratic conditions on a C4 analytical column
(Waters, 0.39 x 30 cm). Quantitative amino acid analysis was performed on HFIP
solutions of the pure peptide using arginine as an internal standard. The
solution was dried and the peptide hydrolyzed with 6 N HCl + 0.1% phenol
(1100 for 24-48 hr). The samples were then derivatized with
phenylisothiocyanate and analyzed using the Waters Picotag@ system. Peptides
were analyzed by both Plasma Desorption and FAB mass spectrometry. A single
parent ion corresponding to M+H+ or M+Na+ was observed for each peptide,
and the fragmentation pattern observed in the FAB mass spectrum verified the
sequence. 1H NMR spectra (see appendix) in DMSO solution were recorded for
each peptide and were consistent with the proposed structure.
OsmB(28-44)
Amino Acid Analysis: S 0.9(1) G 7.0(7) T 1.8(2) A 2.0(2) V 1.6(2) I 0.8(1) L 2.3(2).
RPHPLC: C4 prep (5 x 25 cm), 77/23 H2 0/CH3CN (0.1% TFA), 80 ml/min,
VR=310 ml. C4 analytical (0.4 x 30 cm), 82/18 H2 0/CH3CN (0.1% TFA), 2
ml/min, VR=42 ml.
FABMS: 1428.0 (calc. 1427.8).
NMR: (300 MHz, DMSO, characteristic resonances only) 6 0.80 (m, 30H, Leu, Ile,
Val CH 3 ), 1.04 (m, 6H, Thr CH 3), 1.20 (d, 6H, J=7.0, Ala CH 3), 1.5-1.7 (m, 9H, Leu,
Ile P H & yH), 1.85 (s, 3H, acetyl), 1.95 (m, 2H, J=6.5, Val PH), 7.05 (s, 1H,
CONH2), 7.17 (s, 1H, CONH 2), 7.6-8.2 (m, 17H, NH).
OsmG3
A. A. Anal.: S 0.9(1) G 7.6(7) T 2.0(2) A 2.0(2) V 1.9(2) 1 0.9(1) L 2.3(2).
RPHPLC: C4 prep (5 x 25 cm), 76/24 H2 0/CH3CN (0.1% TFA), 80 ml/min,
VR=870 ml. C4 analytical (0.4 x 30 cm), 80/20 H2 0/CH3CN (0.1% TFA), 2
ml/min, VR=50 ml.
NMR: (300 MHz, DMSO, characteristic resonances only) 6 0.80 (m, 30H, Leu, Ile,
Val CH 3), 1.05 (m, 6H, Thr CH 3), 1.20 (t, 6H, J=7.0, Ala CH 3), 1.5-1.7 (m, 9H, Leu,
Ile PH & yH), 1.83 (s, 3H, acetyl), 1.95 (m, 2H, J=6.5, Val PH), 7.07 (s, 1H,
CONH 2), 7.21 (s, 1H, CONH2), 7.7-8.2 (m, 17H, NH).
OsmA
A. A. Anal.: S 1.1(1) G 4.4(4) T 1.9(2) A 4.9(5) V 1.8(2) I 0.9(1) L 2.4(2).
RPHPLC: C4 prep (5 x 25 cm), 70/30 H20/CH3CN (0.1% TFA), 80 ml/min,
VR=360 ml. C4 analytical (0.4 x 30 cm), 67/23 H20/CH3CN (0.1% TFA), 2
ml/min, VR=51 ml.
FABMS: 1469.8 (calc 1469.8).
NMR: (300 MHz, DMSO, characteristic resonances only) 5 0.80 (m, 30H, Leu, Ile,
Val CH 3 ), 1.04 (m, 6H, Thr CH 3), 1.2 (m, 15H, Ala CH 3), 1.6-1.8 (m, Leu, Ile PH &
yH), 1.83 (s, 3H, acetyl), 1.95 (m, 2H, J=7.1, Val PH), 7.05 (s, 1H, CONH2), 7.17 (s,
1H, CONH 2), 7.6-8.2 (m, 17H, NH).
Electron Microscopy.
Peptides were aggregated as described beloW in the standard phosphate
buffer at 200-400 pM. Small aliquots of suspended aggregate were placed on
73
carbon-coated copper grids and allowed to bind. Excess suspension was
removed by rinsing the grids with distilled water. The grids were stained with
2% (w/v) uranyl acetate and then rinsed. Samples were viewed in a JOEL
1200CX electron microscope operating at 80 kV, typically at 60K-120K
magnification.
Congo Red Staining and Birefringence.
A suspension of peptide fibrils in water was allowed to dry on a glass
microscope slide. The peptide film was immersed in a solution containing 1 mM
Congo red, 100 mM NaCl, 10 mM phosphate, pH 7.4 for 1 min, then rinsed by
immersing in distilled water for 1 min and dried. Birefringence was determined
with a Wild Leitz M3Z light microscope equipped with a polarizing stage.
Fourier-Transform Infrared Spectroscopy.
Aggregated peptides were collected by centrifugation and spread evenly
on a CaF2 plate. After air drying, excess salt was removed by soaking the solid in
H20 for one minute. The remaining aggregate was dried in vacuo. The spectra
were recorded at 2.0 cm- 1 resolution on a Perkin-Elmer 1600 series FTIR
spectrometer. The interferograms from 16 scans were averaged and the
contribution from air was subtracted. Spectra were smoothed to improve the
signal to noise ratio; the extent of smoothing was identical for each sample. Peak
positions were determined with the aid of second derivative analysis.
Circular Dichroism Spectroscopy.
Circular dichroism spectra were recorded on an AVIV 60DS
spectrapolarimeter in the laboratory of Dr. Robert Sauer, Department of Biology,
MIT. Quartz cells of 0.1-cm path length were obtained from Hellma, 0.01 and
0.001-cm path length cells were obtained from Starna. A stock solution of each
peptide (-1 mM) was prepared in HFIP. The exact concentrations were
determined by quantitative amino acid analysis. Aliquots of this solution were
transferred to 1.5 ml Eppendorf tubes and the HFIP was removed in vacuo. The
peptide was dissolved in the appropriate solvent by sonicating for several
seconds. The standard buffer used for CD was 100 mM KF, 8.2 mM K2HPO4, 1.8
mM KH 2PO4, pH 7.4. This is similar to the buffer used for aggregation
experiments, except that Na+ and Cl- was replaced by K+ and F- to minimize
scattering effects below 210 nm. In some cases, the solution was supersaturated,
but did not aggregate during the CD experiment. Concentration-dependence of
the CD spectrum was studied by dissolving the peptide at 10 tM in 50 ml of
distilled water. After recording the CD spectrum, the solution was concentrated
2-5-fold on a rotary evaporator, using a water bath to keep the sample
temperature at -25'C. The relative concentration was determined by absorbance
at 225 nm, the CD spectrum was recorded, and the procedure was repeated.
Each sample formed an insoluble solid at high concentration, this concentration
was estimated by the volume of the system at the time of aggregation. Each
spectrum was scanned three times from 250 to 190 nm, with 1 rn steps and 1.0
sec averaging. Solvent and cell backgrounds were subtracted from each sample.
Spectra were recorded at 25'C except where noted. Data displayed in Figures 2.6
and 2.7 were smoothed with a 5-point smoothing function. Secondary structural
analysis was performed prior to smoothing by the method of Morrisett 39,40 which
is based on reference spectra derived from polylysine. This method calculates
the percentage of helical structure based on the molar ellipticity at 222 nm:
( 222 + 3000)
%YO a helix =
(36000 + 3000)
Peptide Solubility.
Attempts to determine the solubility of each peptide by directly dissolving
the lyophilized peptide gave erratic results. To determine the thermodynamic
solubility of each peptide, a supersaturated solution of the peptide in 100 mM
NaCl, 8.2 mM Na2HPO4, 1.8 mM NaH 2PO 4 (pH 7.4, same buffer used in all
experiments unless stated otherwise) was stirred for a few days to initiate
aggregation, and then allowed to aggregate and equilibrate over 3 to 4 weeks (as
described in the kinetics section below). Stirring is believed to fragment existing
fibrils, resulting in formation of excess seeds; this is described in more detail
below. Stirring prevents the cessation of fibril growth that was observed in
seeding experiments from limiting the measured solubility. The aggregate was
removed by centrifugation and the supernatant was filtered through Millex-GV
0.22 pm aqueous filters. Peptide concentration was determined by the BCA
protein assay6' using standards of the same peptide which had been previously
calibrated by quantitative amino acid analysis. Results were reproducible to
within ±5 %.
Kinetic Aggregation Studies.
In order to prepare a supersaturated aqueous solution from which
aggregation could occur, each peptide was first dissolved in HFIP at 1-2 mM and
then the HFIP was removed, either with a gentle stream of nitrogen, or in vacuo,
until the peptide formed a clear film. This film could be redissolved in Milli-Q
water, resulting in 0.2-1 mM solutions. Further drying of the HFIP film resulted
in a less soluble white solid. Attempts at dissolving lyophilized peptide proved
unsuccessful. The peptide solution was then filtered through 0.22 pm filters and
the concentration determined by the BCA assay. The solutions were used
immediately in aggregation assays, since delays of more than a few hours
resulted in partial aggregation of these stock solutions. The peptide solutions
were diluted to the appropriate concentration in 900 ptl and a concentrated salt
solution (1 M NaCl, 82 mM Na2HPO4, 18 mM NaH 2PO 4, pH 7.4, 100 pil) was
added, to afford the standard buffer conditions (100 mM NaCl, 8.2 mM
Na2HPO4, 1.8 mM NaH 2PO 4, pH 7.4). The addition of salt was considered the
initiation point for aggregation. This assumption may not have been valid, but
the sample preparation procedure lasted only ~1 hr, so the error introduced in
the aggregation assays was minimal. Turbidity data were collected at 400 nm vs.
a blank containing the buffer solution only. The peptide solutions were vortexed
slightly before each absorbance measurement to distribute the peptide fibrils
evenly throughout the solution. Prolonged agitation was avoided as it was
found to accelerate peptide aggregation (discussed in more detail below).
To study the kinetics of seeded growth, the peptide aggregates were
formed by stirring 250 pM solutions for 15 hr. These aggregates were sonicated
for 15 min, and an aliquot of this fibril suspension (50 1al, 12.5 nmol) was added
to 950 pl of a 250 pM peptide/buffer solution. The solution was vortexed and the
turbidity monitored at 400 nm for 30 min with no further agitation.
Problems Associated With Kinetic Aggregation Studies
Several points are worth mentioning with regard to the experimental
procedures used in measuring aggregation. First, we have used turbidity as a
measure of the amount of aggregate in a sample. Our experiments have
indicated that this is generally (but not absolutely) true. Turbidity has been used
by to study hemoglobin polymerization, and was as sensitive as other methods
such as light scattering and fluorescence based assays. 47 Berne showed that this
is valid in a dilute suspension of rod-shaped particles. 48 However, we have
found that the turbidity of solutions is difficult to reproduce. 59 Several identical
samples give final absorbances that may vary by as much as 20% of the
absorbance value. Further, we have observed that the turbidity of completely
aggregated samples begins to decrease after several days.50 Visually, one
observes that an even suspension of microscopic particles is converted to a
clumpy suspension of large particles. We believe that these observations may be
related to the clumping observed by electron microscopy: peptide fibrils
aggregate with each other in a parallel fashion, forming much larger bundles.
This results in deviations from an ideal suspension, and the turbidity is no longer
proportional to the mass of aggregate. We have used turbidity as only a crude
estimate of the amount of aggregate present, and rates derived from this data
should be examined with a little skepticism.
A second key point is the reproducibility of the lag time. We have found
that if aggregation experiments derive from the same stock solution of peptide,
then the lag time is reproducible to within ±10 %. However, experiments which
derive from different stock solutions can vary dramatically. This result can be
explained by the possibly high-order concentration dependence of nucleation.
Our ability to measure and reproduce peptide concentrations is limited by amino
acid analysis, BCA assay, and experimental errors in measurement to ca. 250 ± 15
pM. This range of error has a dramatic affect on the lag time: for a decamer
nucleus, if the lag time at 250 pM is 10 hr, then the range of lag times
encompassed by this reproducibility is 5.9 to 17.4 hr. Given this result, it is
surprising that the lag time can be reproduced at all. Another source of error in
the lag time may be batch-to-batch variations in the purity of each peptide. In
protein crystallization, it is well established that trace impurities can prevent
crystal formation, 49 presumably by binding to prenuclei, preventing efficient
nucleus formation. We have shown that trace amounts of hydrophobic
molecules (aminonapthalene sulfonic acid is one example) can slow nucleation,
but has no affect on growth of fibrils. A similar affect was noted for hemoglobin
polymerization. 62 The same is presumably true of many of the byproducts of
peptide synthesis and deprotection.
Finally, the rate of nucleation and of aggregation appear to be sensitive to
stirring or agitation. The same OsmB(28-44) solution which has a lag time of
several days in an unstirred trial (Figure 2.8) aggregates in a few hours if the
solution is stirred. Agitation has been implicated in the mechanism of aggregate
formation from insulin.63 Insulin requires partial denaturation at a hydrophobic
surface (teflon or air) for aggregation to occur; agitation catalyzes aggregation by
circulating insulin to and away from this surface. However, we have tried
eliminating air from our system, and have tried teflon, pyrex, and steel stir bars,
none have changed the observed aggregation. Furthermore, sonication is
sufficient to cause aggregation to occur within a few hours. We believe that this
effect may be due to the fragmentation of fibrils in agitated solutions. Although
we cannot observe fibrils during the lag time, they are probably produced in
small amounts throughout the early stages of the experiment. Their growth is
length-limited and there is no self-catalysis; these fibrils therefore have little
affect on the bulk sample. The production of new fibrils increases dramatically
as the growth period approaches, resulting in the increase in turbidity which our
experiment detects. However, if the few fibrils produced during the lag time are
fragmented into millions of small pieces, each of these pieces can serve as a
template for the formation of a new fibril. This would result in the kinetics of the
entire sample following the kinetics of the fastest forming fibril. A similar affect
is also observed in protein crystallization. Vibration or agitation of protein
solutions can lead to rapid formation of microcrystals, rather than slow
formation of larger crystals; this is believed to involve fragmentation of growing
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crystals.49 However, since peptide solutions are rather dilute (-0.1 mg/ml), the
volume of aggregate obtained is small relative to the volume of the sample, and
the suspensions tend to settle out after each measurement. In order to measure
the turbidity of each sample, the aggregate must be resuspended, and this
requires gentle agitation of each tube. This may accelerate aggregation slightly,
but is unavoidable, and the best that can be done is to try to treat each sample in
a similar manner.
References
(1) Glenner, G. New. Engl. J. Med. 1980, 302, 1333.
(2) Sipe, J. Annu. Rev. Biochem. 1992, 61, 947.
(3) Glenner, G. New Engl. J. Med. 1980, 302, 1283.
(4) Jung, J.; Gutierrez, C.; Villarejo, M. J. Bacteriol. 1989, 171, 511.
(5) Jarrett, J.; Lansbury, P., Jr. Biochemistry 1992, 31, 12345.
(6) Fraser, R.; MacRae, T. in Conformation in Fibrous Proteins and Related
Synthetic Polypeptides; Academic Press, New York, 1973.
(7) Katzman, R. New Engl. J. Med. 1986, 314, 964.
(8) Eanes, E.; Glenner, G. J. Histochem. Cytochem. 1968, 16, 673.
(9) Glenner, G.; Harada, M.; Isersky, C.; Cuatrecasas, P.; Page, D. Biochem.
Biophys. Res. Comm. 1970, 41, 1013.
(10) Glenner, G.; Terry, W.; Harada, M.; Isersky, C.; Page, D. Science 1971, 173,
1150.
(11) Lansbury, P., Jr. Biochemistn 1992, 32, 6867.
(12) Halverson, K., The Molecular Determinants of Amyloid Deposition in
Alzheimer's Disease, Ph.D. Thesis, Massachusetts Institute of Technology,
1992.
(13) Wisniewski, T.; Ghiso, J.; Frangione, B. Biochem. Biophys. Res. Comm. 1991,
179, 1247.
(14) Colon, W.; Kelly, J. Biochemistn 1992, 31, 8654.
(15) Come, J.; Fraser, P.; Lansbury, P., Jr. Proc. Natl. Acad. Sci. USA 1993, in
press.
(16) Jarrett, J.; Lansbury, P., Jr. Cell 1993, in press.
(17) Pauling, L.; Corey, R. Proc. Nat. Acad. Sci. USA 1953, 39, 253.
(18) Parker, K.; Rudall, K. Nature 1957, 179, 905.
(19) Termine, J.; Eanes, E.; Ein, D.; Glenner, G. Biopolymers 1972, 11, 1103.
(20) Krimm, S.; Bandekar, J. Adv. Protein Chem. 1986, 38, 181.
(21) Wetzel, R. in Stability of Protein Pharmaceuticals: In Vivo Pathways of
Degradation and Strategies for Protein Stabilization; Ahern, T. Manning, M.;
Plenum Press, New York, 1993, in press.
(22) London, J.; Skryzynia, C.; Goldberg, M. Eur. J. Biochem. 1974, 47, 409.
(23) King, J.; Fane, B.; Haase-Pettingwell, C.; Mitraki, A.; Villafane, R.; Yu, M.-
H. in Protein Folding: Deciphering the Second Half of the Gentic Code;
Gierasch, L. King, J.; American Association for the Advancement of
Science, Washington, D. C., 1990; p 225.
(24) Cleland, J.; Wang, D. Biotechnology 1990, 8, 1274.
(25) Halverson, K.; Fraser, P.; Kirschner, D.; Lansbury, P., Jr. Biochemistry 1990,
29, 2639.
(26) Spencer, R.; Halverson, K.; Auger, M.; McDermott, A.; Griffin, R.;
Lansbury, P., Jr. Biochemistn 1991, 30, 10382.
(27) Glenner, G.; Keiser, H.; Bladen, H.; Cuatrecasas, P.; Eanes, E.; Ram, J.;
Kanfer, J.; DeLellis, R. J. Histochem. Cytochem. 1968, 16, 633.
(28) Lucas, F.; Shaw, J.; Smith, S. Nature 1957, 179, 906.
(29) Geddes, A.; Parker, K.; Atkins, E.; Beighton, E. J. Mol. Biol. 1968, 32, 343.
(30) Richardson, J.; Richardson, D. in Prediction of Protein Structure and the
Principles of Protein Conformation; Fasman, G. D.; Plenum Press, New York,
19 8 9 ; p 1.
(31) Chou, K.-C.; Pottle, M.; Nemethy, G.; Ueda, Y.; Scheraga, H. J. Mol. Biol.
1982, 162, 89.
(32) Kyte, J.; Doolittle, R. J. Mol. Biol. 1982, 157, 105.
(33) Chou, P.; Fasman, G. Adv. Enzymol. 1978, 47, 45.
(34) Kam, Z.; Shore, H.; Feher, G. J. Mol. Biol. 1978, 123, 539.
(35) Cooper, J. Lab. Invest. 1974, 31, 232.
(36) Klunk, W.; Pettegrew, J.; Abraham, D. J. Histochem. Cytochem. 1989, 37,
1273.
(37) McGuinness, B., personal communication.
(38) Wilder, C.; Friedrich, A.; Potts, R.; Daumy, G.; Francoeur, M. Biochemistry
1992, 31, 27.
(39) Greenfield, N.; Fasman, G. Biochemistry 1969, 8, 4108.
(40) Morrisett, J.; David, J.; Pownall, H.; Gotto, A., Jr. Biochemistry 1973, 12,
1290.
(41) Marqusee, S.; Robbins, V.; Baldwin, R. Proc. Natl. Acad. Sci. USA 1989, 86,
5286.
(42) Ananthanarayanan, V.; Andreatta, R.; Poland, D.; Scheraga, H.
Macromolecules 1971, 4, 417.
(43) Segrest, J.; Pownall, H.; Jackson, R.; Glenner, G.; Pollock, P. Biochemistry
1976, 15, 3187.
(44) Li, S.-C.; Deber, C. Int. J. Pept. Prot. Res. 1992, 40, 243.
(45) Deber, C.; Brandl, C.; Deber, R.; Hsu, L.; Young, X. Arch. Biochem. Biophys.
1986, 251, 68.
(46) Hilbich, C.; Kisters-Woike, B.; Reed, J.; Masters, C. L.; Beyreuther, K. J.
Mol. Biol. 1991, 218, 149.
(47) Eaton, W.; Hofrichter, J. Adv. Prot. Chem. 1990, 40, 63.
(48) Berne, B. J. Mol. Biol. 1974, 89, 755.
(49) Feher, G.; Kam, Z. Meth. Enzymology 1985, 114, 77.
(50) Beaven, G.; Gratzer, W.; Davies, H. European J. Biochem. 1969, 11, 37.
(51) Lindsey, J. New J. Chem. 1991, 15, 153.
(52) Caspar, D. Biophys. J. 1980, 32, 101.
(53) Chothia, C.; Janin, J. Nature 1975, 256, 705.
(54) Kirschner, M.; Mitchison, T. Cell 1986, 45, 329.
(55) Erickson, H.; Pantaloni, D. Biophys. J. 1981, 34, 293.
(56) Voter, W.; Erickson, H. J. Biol. Chem. 1984, 259, 10430.
(57) Wegner, A.; Engel, J. Biophys. Chem. 1975, 3, 215.
(58) Ingram, V. Biochim. Biophys. Acta 1959, 36, 402.
(59) Hofrichter, J.; Ross, P.; Eaton, W. Proc. Natl. Acad. Sci. USA 1974, 71, 4864.
(60) Kaiser, E.; Colescott, R.; Bossinger, C.; Cook, P. Anal. Biochem. 1970, 54,
595.
82
(61) Smith, P.; Krohn, R.; Hermanson, G.; Mallia, A.; Gartner, F.; Provenzano,
M.; Fujimoto, E.; Goeke, N.; Olson, B.; Klenk, D. Anal. Biochem. 1985, 150,
76.
(62) Burley, S.; Wang, A.; Votano, J.; Rich, A. Biochemistry 1987, 26, 5091.
(63) Sluzky, V.; Tamada, J.; Klibanov, A.; Langer, R. Proc. Nati. Acad. Sci. USA
1991, 88, 9377.
Chapter 3
Kinetic Studies of Amyloid Formation by P Protein Derivatives
In the previous chapter, experiments were described that demonstrated
that fibril formation by peptides similar to the $ protein was nucleation
dependent, and suggested that sequence-dependent effects are important in fibril
formation. While we found that three related sequences could all form
morphologically similar fibrils, the structure of these fibrils was distinct as
demonstrated by the specificity of the seeding effect. The demonstration of a
nucleation-dependent assembly process in AD could have a profound influence
on our understanding of the disease. Slight changes in protein concentrations
which might not be detectable to the scientist or physician could result in a
dramatic acceleration in plaque formation. Of course, demonstration of
nucleation-dependent aggregation in a peptide derived from a bacterial protein
does not present a strong case that all fibril formation is nucleation dependent.
Unfortunately, the synthesis of pure P protein variants had proven difficult,1'2
and the milligram quantities necessary for in vitro aggregation experiments were
not available. At this time, it was known that there were several variants of the P
protein found in plaques, differing at their N- and C-termini. (described in
Chapter 1) The principal components of the plaques were believed to be P1-39 or
01-40 in cerebrovascular deposits, and $1-40 along with either f1-42 or $1-43 in
neuritic plaques.3 4 It had also been reported that P1-39 was more soluble than
P1-42 in vitro, although the N-terminus affected the solubility of both of these
proteins.5-7 We postulated that the C-terminus might play a critical role in the
aggregation process. We synthesized four variants which began at residue 26
and continued through each of the four known C-termini of the naturally
occurring P proteins. In vitro experiments demonstrated that these peptides
aggregate by nucleation-dependent mechanisms, and that the rate of nucleation
was dramatically dependent on the C-terminus. Furthermore, seeding of fibril
formation was not dependent on the C-terminus. This effect may have important
consequences for the disease process.8
Solution Properties of the P Proteins
Amyloid plaques are by definition insoluble protein deposits. However,
the P protein presumably must occur free in solution after excision from 1APP
and prior to plaque formation. The structure of this protein in solution has been
the focus of Zagorski and coworkers.5 ,6,9 They showed initially that 1-39 and
1-42 demonstrated significant levels of P structure at pH 5.4 by CD
spectroscopy. 6 However, centrifugation demonstrated that this structure was
due to a high molecular weight aggregate. The solution structure prior to
aggregation could not be measured due to rapid aggregation at pH 5.4. Above
pH 7 and below pH 4, 1-39 was random coil (compared to polylysine reference
spectra), while p1-42 was an aggregated P structure, although the $ structure CD
ellipticity was less intense than at pH 5.4.5 Addition of TFE to 1-39 resulted in
the formation of helical structure below pH 4 or above pH 7. At pH 5.4, the
peptide formed aggregate, even in the presence of TFE. The hydrophobic C-
terminus, $29-42, showed properties which were similar to 11-42, but with no pH
dependence. The N-terminus, 11-28, was also relatively insoluble from pH 4-7,
but was random coil in other pH ranges in aqueous buffer. Addition of TFE
resulted in the formation of helical structure. Using two-dimensional NMR
techniques, they localized this helical structure to residues 1-6 and 11-26 of $1-28,
with an intervening unstructured loop from residues 7-10.9 They argue that the
helical structure represents the normal structure at in vivo extracellular pH (7.4),
while P-structure is preferred at the lower pH found in lysosomes (the lysosome
had been implicated as a possible location of plaque formation 10 ). They also
demonstrate that the peptide p1-28 forms an apparently soluble n-structure in a
time- and concentration-dependent manner from TFE/buffer. Size-exclusion
chromatography suggests that this soluble aggregate is tetrameric. Similar
results have been obtained by Hilbich, et al. 11,12 They use CD spectroscopy to
study peptides which have different N-termini and end at residue 43. In pure
water, the peptide P10-43 adopts apparently soluble p-structure. Addition of
NaF (>50 mM) results in precipitation, while the small amount of peptide
remaining in solution was primarily random coil. (A similar observation was
described for the OsmB peptides in Chapter 2) In this case size-exclusion
chromatography suggested the coexistence of monomer and dimer at low salt
concentrations (<50 mM NaF). Hilbich also attempts to measure the relative
solubilities of several peptides derived from the P protein.* In aqueous solution,
those peptides which contain only the N-terminal region are relatively soluble
(>70% dissolved), while all peptides which contain the entire C-terminal region
through residue 43 were found to be relatively insoluble. They also synthesized
$10-42 "mutants" in which residues 13-14 (His-His) were replace by Ala-Ala.
This resulted in very low solubility, suggesting that these residues play an
important role in maintaining a soluble structure. Finally, FTIR spectroscopy
confirms that 1-40 is unstructured at high (>10.5) and low (<2.5) pD; a broad
* They report that the apparent solubility was a function of the total amount of peptide they
attempted to dissolve. Therefore, they report the solubility as a percentage of a 0.5-2 mg/ml
suspension. Solubility should be independent of concentration. Their observation indicates
either that the suspensions had not reached thermodynamic solubility, or that their peptides
were impure.
band was observed in D20 at 1645 cm-1.13 At the high concentrations required
for FTIR (3-5 mg/ml), $-structured gels were formed at all other pHs.
Aggregation Properties of # Proteins
As was apparent above, it is difficult to distinguish the soluble properties
of the P protein from the aggregation properties. Observation of soluble fs-
structure5 11 may in fact represent formation of aggregates which are initially
fibrous gels, but eventually form particulate.14 Size-exclusion chromatography
may suggest high concentrations of oligomers, but small peptides often elute
more rapidly than expected from such systems, and large aggregates may not
elute at all. Burdick, et al. have studied the aggregation properties of synthetic P
proteins.7 They assay the "percent solubility" in 0.75 mg/ml solutions (see
previous footnote), and demonstrate that the peptides are "soluble" above pH 7.4
and below pH 3. Similar results were obtained by Zagorski5 and Hilbich,11 who
noted the formation of P structure and eventual aggregates between pH 4 and 7.
Burdick, et al., also show that in their assay, after a 6 hr incubation at -300 gM,
1-42 and $1-39 were similarly soluble: -0.03 mg/ml (0.1 gM). Finally, they
show that aggregates formed in aqueous buffer dissociate into tetramers and
monomers in detergents. Treatment with strong acid (formic acid and TFA)
partially dissolves the aggregate. The same authors have demonstrated that the
formation of aggregates is time-dependent, and that the aggregated form is toxic
to cultured neurons.15,16
The time-dependence of aggregation has been recognized previously,
although nucleation-dependence was not observed. Tomski and Murphy
studied the kinetics of 1-40 aggregation in aqueous solution (pH 7.4) at
relatively high concentration (2 mg/ml, -500 gM).1 7 Aggregation began
immediately and exponentially approached equilibrium over 15 days. Quasi-
elastic light scattering data was consistent with rod-shaped particles 4.8 nm in
diameter with molecular weights in the range of 106 - 107 (250 to 2500
monomers). Although they note that the aggregation is slow, they then proceed
to describe a model in which aggregation is diffusion-limited and each step is
essentially irreversible. It would seem that this model does not describe their
own data. While Zagorski has noted the time-dependence of p-structure
formation in the CD spectra of 01-42 and P29-42, he does not present this data in
the literature.5 Fraser, et al., used FTIR to follow the formation of D structure by
p1-40 in D20 at pH 2.13 At 5 mg/ml, structure formation began immediately and
reached equilibrium after -24 hr. Maggio, et al., have observed the "growth" of
amyloid plaques in brain homogenates from AD brains.18 They prepare
radioiodinated P1-40, and observe that at picomolar concentrations, it saturably
binds to plaques in AD brains, with an apparent 1/2 of ~7 hrs. The bound
peptide dissociates readily with an apparent t1/2 of -1 hr. Since the on-rate is
slower than the off-rate at these concentrations, these experiments must not
represent sustained growth. More likely, the association actually represents
exchange between radiolabelled peptide in solution and cold peptide in the
plaques, and not actual growth of the plaques. Assuming that the synthetic
peptides are truly exchanging into a plaque-like structure, these experiments
demonstrate that AD plaque formation is readily reversible, since addition of
fresh buffer resulted in the time-dependent dissociation of the labelled peptide.
More recent experiments by the same laboratory demonstrate that metal ions
may play a role in P protein aggregation.19 Addition of aluminum, iron, and zinc
(millimolar concentrations) result in rapid aggregation of the peptide at
picomolar concentrations. Other ions had no affect. Protein cross-linking may
play a role in preventing disaggregation in vivo. 20 Aggregation in the presence of
Fe-EDTA resulted in the formation of a covalently crosslinked aggregate. The
radical scavenger ascorbate inhibited this process. Localized inflammation
results in impairment of radical scavenging systems and this may provide a
mechanism for in vivo cross-linking.
In summary, the conversion of an essentially random solution structure to
insoluble p-structure has been recognized in studies of various p protein
derivatives. The N-terminus modulates this affect in a pH dependent manner; in
particular, His13-His14 seem to be important as the pH is lowered from pH 7.4 to
pH 5. The hydrophobic C-terminus is believed to be responsible for the high
insolubility. In particular, the addition of 3 residues between 1-39 and 1-42
seems to be very important. Prior to the work described in this chapter, it was
believed that 1-39 and 1-42 have different solubilities. In addition, aggregation
was believed to progress via a slow but spontaneous pathway, resulting in an
exponential growth curve. We have demonstrated that this is due to the
relatively high concentrations that previous researchers have worked with, often
in excess of 1 mg/ml. We demonstrate that at 10-100-fold lower concentrations,
which approach those concentrations found in vivo, aggregation proceeds via a
nucleation-dependent mechanism.
Aggregation of Truncated C-Terminal P Protein Variants
As described above, the hydrophobic C-terminus was believed to be
responsible for the high insolubility of the P protein, especially P1-42. It was
surprising, however, that three residues could account for such a large difference
in solubility between 1-39 and 11-42, as had been reported.6,11 A simple
calculation of the difference in hydrophobicity between 1-39 and p1-42 suggests
that the solubility of 1-42 should be ~80% of the solubility of 01-39.21 In the
context of a nucleation-dependent mechanism for fibril formation, we suspected
that the observed differences might be due to a kinetic effect, rather than a true
Figure 3.1
Sequence of p protein and model peptides
1 26 43
p protein: H2N-DAEFRHDSGYEVHHOKLVFFAEDVGSNKGAIIGLMVGGVVIAT-CO 2H
$26-43: AcHN-SNKGAIIGLMVGGVVIAT-CO 2H
$26-42: AcHN-SNKGAIIGLMVGGVVIA-CO 2H
p26-40: AcHN-SNKGAIIGLMVGGVV-CO 2H
$26-39: AcHN-SNKGAIIGLMVGGV-CO 2H
thermodynamic solubility. At this time, Kurt Halverson in our lab had shown
that a unique structure was present in the peptide f34-42 corresponding to the C-
terminal region of p1-42.22 We believed that this might play a role in the
observed differences in the properties of the C-terminal variants. As Hilbich and
Zagorski had noted, the N-terminus seemed to play a more complex, pH-
dependent role in the solubility of the P-proteins. To avoid the issue of pH
dependence, and to ease peptide synthesis and purification required, we chose to
study model peptides which began at Ser-26 and extended to each of the four
reported C-termini. (Figure 3.1)
Model Peptides Form Amyloid Fibrils
Each model peptide was soluble in DMSO (-5-10 mg/ml). Addition of a
DMSO solution to stirred aqueous buffer resulted in the eventual formation of a
turbid suspension. These precipitates were collected by centrifugation and
visualized by electron microscopy. (Figure 3.2) 026-39 formed thick rods (150-
200 A). These may be bundles of smaller fibrils as suggested by the variation in
thickness along each rod, however, at the resolution of these micrographs, this is
difficult to determine. p26-40 formed thin fibrils (-50 A) which bundled into
loosely packed clumps, reminiscent of the morphology of in vivo plaques.13 2 3
p26-42 formed short twisted fibrils -100 A in diameter and 1000 A long. 126-43
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Figure 3.2
Electron micrographs of fibrils formed from D26-39, [26-40, D2642, $26-43, and
fibrils formed by seeding p26-39 with p26-42, and p26-40 with p26-43.
Bar = 1000 A.
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formed very thin fibrils, <5 A in diameter, which associated in long parallel
bundles. Unlike hemoglobin and tubulin fibrils described in chapter 2, in which
the monomers are easily visualized, the individual peptide monomers are too
small to be visualized, due to the limitations of electron microscopy. Thus,
electron microscopy offers little help in understanding the mechanism of
formation or structure of peptide fibrils. It is perhaps sufficient to note that the
addition of a single amino acid at the C-terminus results in differences in the
observed fibrils. These differences may be related to structural differences at the
molecular level, yet it is also possible that the peptides are structurally similar,
and that differences are due to different packing arrangements within the fibril.
As will be described in chapter 4, this latter possibility is supported by our data.
Table 3.1
Solubility of model peptides in buffer.
Peptide Solubility (gM) Std. Dev. (3 trials)
P26-39 7.5 ±2.5
p26-40 4.5 ±2.5
P26-42 0.7 ±0.3
P26-43 2.0 ±1.0
Solubility is Slightly Sensitive to C-Terminus
Supersaturated aqueous solutions of each peptide were prepared and
stirred to accelerate aggregation. After stirring for one week to drive the process
to thermodynamic equilibrium, the samples were centrifuged and filtered. The
concentration of each peptide was determined by amino acid analysis. The
shorter variants, 26-39 and $26-40, were -2-5-fold more soluble than the longer
variants, $26-42 and $26-43. This difference in solubility was less than had been
Figure 3.3
Aggregation of P protein variants as indicated by the turbidity at 400 nm. All at
200 pM initial concentration. Note the discontinuous x-axis. Curves are drawn
by hand.
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previously reported,11 but was more than would have been expected due to
simple hydrophobicity. The relative solubility of 026-39 and f26-42 can be
calculated from simple hydrophobicity considerations.* Simple hydrophobicity
increases would predict that p26-39 would be only 1.7-fold more soluble than
p26-42, however, we observe that it is 5-10-fold more soluble. This suggests that
the differences in solubility observed are due primarily to differences in the
structure of the fibrils.
This is based on the relative free energy of transfer of model peptides from alcohol into water.
The average transfer free energy is calculated over all of the residues and the change in solubility
is assumed to be proportional to the change in average transfer free energy.
Time-Dependence of Aggregation is Sensitive to C-Terminus
Stock solutions of each peptide were prepared in HFIP and calibrated by
amino acid analysis. An aliquot of each peptide (200 nmol) was dried and
dissolved in DMSO. The DMSO solution of each peptide (200 nmol in 50 gl) was
added to an aqueous buffer and fibril formation was followed by monitoring the
turbidity at 400 nm. (Figure 3.3) 026-43 and 126-42 aggregated immediately
under these conditions (200 gM). At the lowest concentration which could be
followed using turbidity (40 gM), 126-42 still aggregated immediately, while P26-
43 had a delay time of 5-10 sec. (data not shown) 26-40 and 126-39 showed
significant lag times before fibril growth occurred. At 200 pLM, 126-40 had a lag
time of 12 hr, while $26-39 had a lag time of 60 hr. Increasing the concentration
of each to 500 pM resulted in immediate aggregation of P26-40, while 126-39 had
a lag time of -24 hr.
As described in chapter 2, regardless of the model used to describe the
nucleation process, the concentration dependence of the delay time is indicative
of the number of monomers involved in the formation nucleus. For any peptide
demonstrating different delay times at two concentrations:
n = ln(t2/t1) / ln(C1/C2)
$26-40 showed a lag time of 12 hr at 200 pM and <10 sec at 500 pM. The size of
the nucleus suggested by this limited data is n=7-8. However, a similar
calculation for $26-39 gives the size of the nucleus as n=1. However, long lag
times are difficult to measure, due to experimental difficulties discussed in
chapter 2, thus data for $26-39 may not be reliable. In an attempt to understand
the concentration dependence of aggregation, we explored the aggregation of
126-40 at concentrations between those described above. (Figure 3.4) In
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Figure 3.4
Concentration dependence of P26-40 aggregation. (o) 400 .M, (A) 350 p.M, and
(0) 300 M. Approximate delay times are indicated. Curves are drawn by hand.
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preliminary experiments, it appears that the nucleation effect is not as straight-
forward as we first suspected. Intermediate concentrations, for example 300 pM
in Figure 3.4, initially demonstrate slow exponential growth. This is followed by
a later rate acceleration, which results in an inflection point in the kinetic curve.
Using the inflection point as a measure of the delay time, the values of n obtained
are n=3-5 between 400 and 350 pM, and n=8-14 between 350 and 300 pM (ranges
indicate difficulty in pinpointing the inflection due to limited data). One model
which might explain these curves is the two-step collision model proposed in
chapter 2:
M
M+M ' M*M . 2 M2*M
M
M*M*M .- *M*M*M*M
In this model, the rate-limiting step in nucleus formation is the conversion of a
collision complex into a more stable, possibly structured oligomer. Most
collision complexes dissociate back to monomers before this step can occur. At
higher monomer concentrations, a monomer may collide with the unstable
complex before dissociation can occur. Rapid aggregation can occur via the
lower pathway, in which unstable, perhaps unstructured aggregates build up in
solution. If these become large enough, they may become stable due to size, 24 as
well as due to partial structure formation, and this may initially bypass the rate-
limiting steps in nucleus formation. Later, peptide which is aggregating via the
upper rate-limited pathway may eventually reach nucleation, and a second burst
of growth would be observed. At very high concentrations, virtually all of the
peptide may aggregate via the lower non-nucleation-dependent pathway; this
may account for differences in fibril morphology between the same peptide
aggregated at high versus low concentrations. (This was observed for OsmB in
Figure 2.4.)
Seeding Results in Immediate Aggregation
If fragmented P26-40 fibrils from a previous experiment are added as
seeds to a supersaturated solution of P26-40, immediate fibril growth occurs.
(Figure 3.5) Similar results are obtained for p26-39. This seeded fibril growth is
relatively slow, with a t1/2 - 15-20 min, while P26-42 and P26-43 have a t1/2 of <
5 sec under the same conditions. This suggests that the effects which
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result in rapid nucleation have a similar affect on the growth rate. However,
seeded growth is much more rapid than unseeded growth, (Figure 3.3) which has
t1/2 - td - 5 hrs. As described in chapter 2 for the case of OsmB, one explanation
of this rate difference is that fibril growth is limited to a finite length, and that
even during the growth phase, the homogeneous nucleation of new fibrils is rate-
limiting.
Figure 3.5
Seeding of p26-40 aggregation. (A) A solution of P26-40 (200 nmol in 950 gl) was
seeded with $26-40 fibrils (20 nmol in 50 g1). (o) A solution of p26-40 (200 nmol
in 950 p) did not aggregate within 8 hr. Curves are drawn by hand.
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f26-39 and 126-40 are Seeded by All of the C-Terminal Variants
If the seeding experiment described above is repeated with seed fibrils
prepared from each of the other three variants, immediate fibril growth occurs.
This was surprising since this was not the case for the OsmB derived peptides
described in chapter 2. Furthermore, if a small amount (20 nmol) of @26-42 or
$26-43 seed peptide is mixed in DMSO with the primary peptide (200 nmol, 10
mole % seed peptide), followed by coaddition to the aqueous buffer, then
seeding also occurs. (Figure 3.6) The rapidly aggregating seed peptides may
form fibrils within the first minute at this concentration, and these fibrils seed the
aggregation of the primary peptide. The rate of heterogeneous seeded growth is
only slightly slower than the rate of homogeneous seeded growth. For instance,
P26-40 seeded with its own fibrils (Figure 3.5) has a t1 /2 - 15-20 min, but when
seeded with $26-43 (Figure 3.6), t1 /2 - 75 min. This difference suggests there
may be imperfect matching between the structure of the seed surface and the
monomer, but that this difference is not enough to prevent seeding.
Fibril Growth is Reversible
126-40 and 126-43 were prepared which with a tritium label in the N-
terminal acetyl. Fibrils were formed from these peptides as described above and
allowed to age unperturbed in the original buffer. The disaggregation of these
fibrils was measured over time (see experimental section for details). (Figure 3.7)
$26-40 and $26-43 redissolved at similar rates, with t1/ 2 - 5 hr. The differences
observed resulted primarily from the difference in solubility between $26-40 and
126-43. The solubilities observed are consistent with the range of solubilities
observed in the experiments described above (p26-40: 5 ±3 gM, 126-43: 2 ± 1 tM).
Fibrils of 126-40 formed by seeding with 126-43 were not significantly more
stable than unseeded P26-40 fibrils. If one assumes that 126-40
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Figure 3.6
Seeding of p26-39 and P26-40 aggregation with p26-42 and P26-43, respectively.
(0) Primary peptide (200 nmol) and seed peptide (20 nmol) were mixed in
DMSO (50 l) and added to buffer (950 gl). Both primary peptide (q, 200 nmol)
and seed peptide ( A, 20 nmol) alone showed little increase in turbidity during
this time. Curves are drawn by hand.
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Figure 3.7
Disaggregation of peptide fibrils after 1 day of aggregation. (o) $26-40 (60 nmol
total); (0) $26-40 (60 nmol) seeded with 026-43 (6 nmol); (A) p26-43 (60 nmol).
3H-labelled peptide fibrils were pelleted and suspended in fresh buffer.
Concentration is calculated from counts in a 0.2 ptm filtered aliquot. Curves are
drawn by hand.
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and $26-43 form similar numbers of fibrils, then the fact that they have similar
t1 /2 suggests that the initial rate of disaggregation (kr) for p26-43 is about 1 / 10th
of that for $26-40. This suggests that the differences in solubility can primarily be
accounted for by differences in kr, which depends on the structure of the fibrils.
This is consistent with the conclusion reached in the solubility section discussed
above, that the decreased solubility of P26-43 is due primarily to structural effects
rather than hydrophobicity.
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Fibrils Become More Stable Over Time
If the disaggregation experiments described above are repeated after
allowing the fibrils time to age, then it appears that the fibrils become more stable
over time. (Figure 3.8) For $26-40, the rate of disaggregation slows significantly
after 3 days aging, and slows even more after 1 week. A similar result is
observed for 026-43. This maturation process may be due to structural
rearrangements within each fibril, resulting in eventual formation of a minimum
energy packing arrangement, whereas the initial aggregate may represent a
mixture of slightly less stable packing arrangements. It is not clear from this
preliminary data whether the stabilization is a thermodynamic or kinetic effect.
In other words, this stabilization may affect only kr, in which case the rate of
disaggregation is slowed and the final solubility is decreased, or the stabilization
may affect both kr and kf, in which case the solubility of the peptide may or may
not change over time. Long term experiments (2-4 weeks) with more data are
needed to discern between these possibilities.
Model for Amyloid Formation in AD
Amyloid fibril formation from the peptides P26-39 and P26-40 follows
nucleation-dependent kinetics. In subsequent experiments, Elizabeth Berger in
our laboratory demonstrated that the full length proteins also follow nucleation
dependent kinetics: 1-40 and 1-39 have lag times of days to weeks before fibrils
begin to grow, while p1-42 nucleates immediately.8,25 p1-40 and p1-39 can be
seeded by $1-42. This suggests several possible scenarios for amyloid formation
in Alzheimer's disease. (Figure 3.9) Since nucleus formation is highly
concentration-dependent, slight increases in in vivo P protein concentration may
result in dramatic increases in the rate of plaque formation. (Figure 3.9A) A
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Figure 3.8
Stabilization of fibrils over time. Disaggregation of fibrils formed by P26-40 and
f26-43 after (o) 1 day, (0) 3 days, and (A) 7 days. Procedure is described in
Figure 3.6 and in the text. Curves are drawn by hand.
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Figure 3.9
Possible scenario's for amyloid formation in AD. (A) Overproduction of (1-40
results in supersaturation followed by fibril formation. (B) Production of p1-42
results in rapid nucleation and seeding of $1-40 fibril formation. (C) A
heterologous seed (lipid or proteoglycan?) may nucleate fibril formation. (D)
Amyloid fibrils may become more stable over time, resulting in dense plaque
formation.
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recently discovered Swedish family carries a mutation just outside of the P
protein sequence (KM -> NL) that, when expressed in in vitro cell lines, results in
6-11-fold higher levels of ( protein production. 26,27 This increase, assuming n=5-
10, would result in a 104 to 1010-fold acceleration in amyloid formation. A
second possibility suggested by our seeding experiments is that coproduction of
a small amount of (1-42 along with normal amounts of (1-40 results in the more
rapid nucleation and fibril growth. (Figure 3.9B) (1-40 has been detected in
biological fluids28 and is believed to be the "normal" P protein. The proximity of
several mutations to the C-terminus of the ( protein suggests that these may alter
the C-terminal processing, resulting in the formation of (1-42. The possibility
also exists that (1-42 is the primary ( protein in certain diseased individuals; this
would result in rapid amyloid accumulation. Many authors have suggested that
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a protein, lipid, or inorganic substance may act as a heterologous seed for
amyloid formation. 23 (Figure 3.9C) Finally, amyloid fibrils may mature over
time, resulting in decreased solubility and resistance to proteases. (Figure 3.9D)
Binding of proteoglycans and radical-mediated covalent crosslinking may be
involved in this process. 20
Experimental
Synthesis and Purification of Peptides
The peptides P26-39, P26-40, P26-42, and f26-43 were synthesized on the
PAM resin using standard (Boc/benzyl) synthetic protocols. Serine was
protected as the benzyl ether, and lysine was protected as the
o-chlorobenzyloxycarbonyl derivative. A later synthesis used the
fluorenylmethoxycarbonyl-lysine derivative with similar results, although this
peptide required deprotection with piperidine/DMF (1:1) prior to purification.
After coupling of the final residue, the N-terminus was deprotected (50%
TFA /CH 2Cl 2) and acetylated (Ac2O, 10 eq.; DIEA 10 eq.; CH 2Cl2, 4 hr). Peptide-
resin was washed with DMF and CH 2Cl 2, and dried in vacuo. The peptide-resin
was deprotected with TFMSA/dimethyl sulfide/TFA (1:3:5) at 00C for 2 hr,
washed with dichloromethane, and dried in vacuo. The peptide was removed
from the resin with TFMSA/thioanisole/m-cresol/TFA (1:1:1:10) at 0*C for 1h,
and the supernatant was precipitated and washed with diethyl ether. The crude
solid was dried in vacuo. The peptides $26-39 and P26-40 were dissolved in
DMSO (5-10 mg/ml), filtered through Millipore 0.45 .tm teflon filters, and
purified by RPHPLC (purity >90% by isocratic elution). The peptides P26-42 and
126-43, due to their insolubility in water, were purified by gel permeation HPLC
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in hexafluoroisopropanol (HFIP) on a Waters ultrastyragel-HT 103 A column.2
Peptides were analyzed by PDMS and produced the expected parent ion. The
purity of each peptide based on PDMS and amino acid analysis was > 90%.
Fragments observed in the PDMS spectrum confirmed the sequence from the C-
terminus to Lys28.
PDMS: (M+H+) 1358.3 (calculated 1358.6).
A. A. Analysis (uncorrected): N 1.3 (1 expected), S 0.3 (1), G 4.2 (4), A 1.1 (1), V
2.0 (2), M 0.8 (1), I 2.0 (2), L 1.0 (1), K 0.9 (1).
HPLC: YMC C4 semiprep (2.0 x 25 cm) column, 25 ml/min, 75/25 H20/CH3CN
(0.1% TFA), VR = 150 ml.
f26-40
PDMS: (M+H+) 1457.8 (1457.8).
A. A. Analysis: N 0.8 (1), S 0.2 (1), G 4.3 (4), A 1.1 (1), V 2.8 (3), M 0.8 (1), I 2.3 (2),
L 1.1 (1), K 0.7 (1).
HPLC: YMC C4 semiprep (2.0 x 25 cm) column, 25 ml/min, 77/23 to 63/37
(linear gradient over 10 min) H20/CH3CN (0.1% TFA), VR = 160 ml.
p26-42
PDMS: (M+H+) 1642.0 (1642.0).
A. A. Analysis: N 0.4 (1), S 0.3 (1), G 4.4 (4), A 2.3 (2), V 3.0 (3), M 0.7 (1), I 3.1 (3),
L 1.0 (1), K 0.7 (1).
HPLC: Waters ultrastyragel-HT 103 A column, 0.5 ml/min HFIP, fractions
pooled = 5 to 8.5 ml.
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PDMS: (M+H+) 1743.0 (1743.1).
A. A. Analysis: N 0.7 (1), S 0.4 (1), G 4.9 (4), T 0.7 (1), A 2.6 (2), V 3.1 (3), M 0.8 (1),
I 2.8 (3), L 0.9 (1), K 0.6 (1).
HPLC: Waters ultrastyragel-HT 103 A column, 0.5 ml/min HFIP, fractions
pooled = 5 to 9 ml.
Tritiated peptides were synthesized stepwise as described above,
however, prior to N-terminal acetylation, 3H-NaOAc (0.2 eq, 87 mCi/mmol),
BOP (5 eq), DIEA (10 eq) were added to the peptide-resin (200 mg, 0.057 mmol)
in DMF (2 ml) and stirred 2 hr. Cold AcOH (5 eq) was added and the solution
stirred 2 hr. The resin was washed (DMF, CH 2Cl2, MeOH) and dried in vacuo.
The peptide-resin was deprotected and cleaved as described above for unlabeled
peptide. The crude peptide was precipitated from TFA solution into ether (3x),
washed with ether, and dried. The peptide was dissolved in DMSO (10 mg/ml),
and this solution added to aqueous buffer (0.5 ml DMSO solution into 9.5 ml
buffer) and the solution stirred for 3 days. The solid peptide was isolated by
centrifugation, washed with water, and dissolved directly in HFIP (-5 mg/ml).
The concentration of this HFIP stock solution was calibrated by BCA protein
assay versus unlabeled standards of the same peptide. Scintillation counting (8
ml scintillant, 2 min averaged) allowed calculation of the activity: P26-40, 13600
cpm/nmol; P26-43, 9540 cpm/nmol. This corresponds to 75% and 52%
incorporation of 3H-acetyl, respectively. PDMS indicated -80-90% purity. The
peptides were used without further purification.
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Thermodynamic Solubility
Peptide (200 nmoles) was dissolved in DMSO (50 pl) and added to an
aqueous buffer (950 pl, 100 mM NaCl, 10 mM NaH2PO4, titrated to pH 7.4 with
1M NaOH, same buffer was used in all aggregation experiments). The mixture
was stirred for at least 3 days (agitation greatly increased the aggregation rate).
The aggregated peptide was removed by centrifugation (2150 x g for 5 min) and
the supernatant was filtered through Millipore GV 0.22 gm filters. An internal
standard (Pro or Arg) was added to the filtrate and, after concentration, the
residue was hydrolyzed (6 N HCl, 1100, 24-48 hr). Amino acid content and
concentration was determined by the Waters Picotag@ amino acid analysis
method.
Kinetic Aggregation Studies
Stock solutions were prepared of each peptide in HFIP and the
concentration determined by amino acid analysis as described above. Aliquots
(20-500 nmol in HFIP) were dried, dissolved in DMSO (50 W), and added to an
aqueous buffer (950 pl) with vortexing to ensure rapid mixing. Addition of HFIP
solutions directly to buffer resulted in immediate aggregation, presumably due
to the presence of P-structure in anhydrous HFIP (see Chapter 2). At various
intervals after mixing, the fibrils were suspended by briefly vortexing each tube
and the turbidity was measured at 400 nm. Turbidity data from 2-3 identical
samples was averaged to provide the final data, deviation was typically about
+10% of the measured absorbance.
Seeding of Peptide Aggregation
Two methods were used to effect seeding:. fibril seeding and in situ
seeding. In both experiments, a peptide solution in DMSO was prepared as
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described above. In seeding with fibrils, a small amount (20 nmol) of fibrils from
a previous experiment were sonicated for 15-30 min and added to the aqueous
buffer (950 pil). The turbidity was measured and this value subtracted from the
subsequent data. The peptide/DMSO solution (50 p1) was added and the
turbidity monitored as described above. In in situ seeding experiments, the
primary peptide and a small amount of the seed peptide were mixed prior to
addition to buffer. For example, P26-40 (200 nmol) and P26-43 (20 nmol) were
mixed in HFIP. The samples were dried, dissolved in DMSO (50 P1) and added
to buffer (950 gl). Again, the turbidity was followed as described above.
Fibril Disaggregation and Fibril Stability
Fibrils were prepared from tritiated peptides as described above in kinetic
aggregation studies. After aging for 1, 3, or 7 days, an aliquot (300 p1, 60 nmol)
was removed. The suspension was centrifuged and the supernatant decanted.
Fresh buffer (3 ml, final concentration 20 .tM total peptide) was added and the
fibrils suspended. At various time points, the suspension was vortexed, and an
aliquot (100 p1, 0.67 nmol) was removed and filtered through Millipore GV 0.22
gm filters. An aliquot (50 pl) of filtrate was added to scintillant and counted, and
the concentration calculated using the activities listed above. Ultimately, the
absolute concentrations depend on the accuracy of an amino acid analysis of the
original standard followed by a BCA protein assay of the tritiated stock solution.
Thus there is significant error in the absolute concentrations calculated (~ ±25%).
However, the relative concentrations within each peptide are not subject to this
error, thus the stabilization effect observed is believed to be real.
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Chapter 4
Structural Studies of Amyloid Formed by p Protein Derivatives
In Chapter 3, experiments were described that demonstrated dramatic
differences between the properties of the p protein C-terminal variants. In
particular, p26-43 and p26-42 nucleated immediately, while p26-40 and p26-39
had lag times of hours to days before forming fibrils. The fibrils produced
appeared slightly different using electron microscopy, however these differences
were uninterpretable in terms of the peptide structure. We wondered whether
the differences in nucleation rate correlated with any observable differences in
molecular structure. FTIR spectroscopy indicated that the faster nucleating
variants (126-43 and $26-42) were primarily a single structure (1-sheet) while
slower nucleating variants (P26-40 and P26-39) had considerably more structural
disorder. We suspected that these structural differences were centered at Gly37-
Gly38, which form a cis amide in amyloid fibrils formed from a shorter peptide,
P34-42.1 We synthesized peptides which were 13C labelled at these two
positions, and studied fibrils formed from these two peptides using techniques
which had been successfully applied to the structure of 134-42, isotope-edited
FTIR and rotational resonance solid-state NMR. Our results indicate that while
there are structural differences at Gly37-Gly38, both of these peptides contain a
cis amide. Furthermore, the structural differences observed in this region fail to
account for all of the differences between the model peptides. Finally,
preliminary experiments are described which attempt to account for differences
in the nucleation rates and for the prevalence of the cis amide in models of the C-
terminal variants of the 1 protein.
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Structure of p Protein Amyloid
Very little is known about the structure of in vivo amyloid plaques,
especially in the case of plaques derived from AD. The general structural
features of a systemic amyloid derived from the immunoglobulin light chain
have been studied in more detail, partly due to its relative abundance in
postmortem tissue. The structural features of this amyloid are described in more
detail in Chapter 2. In short, X-ray diffraction demonstrates the presence of
cross- structure2 similar to that observed in various silk proteins.3 FTIR spectra
of these plaques is dominated by a band at -1630 cm-1, which also indicates the
presence of p-structure. 4 However, FTIR indicates the presence of considerable
amounts of other structures (>50%), while X-ray diffraction is not able to detect
nonrepeating structures. 24 Initial X-ray diffraction studies with plaques derived
from AD brain offered little evidence for the presence of P structure.5 While the
authors describe their results in terms of the cross-P amyloid model initially
described by Glenner, 2 their results are perhaps overinterpreted. In fact, in his
original paper, Glenner describes a similar diffraction pattern: "This very vague
diffraction pattern is characteristic of many dried proteins and offers very little
insight into the structure of this type of globular protein."2
Recent studies of synthetic peptides derived from the P protein sequence
offer stronger evidence that the P protein fibrils contain cross-P structure.
Peptides derived from the N-terminus of the P protein (p1-28 and truncated
derivatives) form fibrils which are morphologically similar to in vivo fibrils.6 The
pH affected the fibril morphology as viewed by EM. FTIR indicated the presence
of primarily P structure in a peptide corresponding to residues 9-28. The
diffraction pattern showed the characteristics of cross-P structure.7 In a later
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study, the full length f protein (1-40) demonstrated similar properties, with
cross-$ structure indicated by X-ray diffraction and $ structure indicated in the
infrared spectrum.8 The model proposed for amyloid by these authors 5 is based
on the cross- model proposed by Pauling for the silk protein from Bombyx mori.9
(Figure 4.1) This low-resolution model has since been refined,10 and is intended
as the simplest structure which satisfies the X-ray diffraction data. The principle
features are antiparallel $ sheets which extend along the fiber axis. (Figure 4.1)
Each peptide strand is aligned perpendicular to the fiber axis. Sheet stacking
gives the fibril its characteristic thickness. (50 to 100 A corresponds to 5-10
stacked sheets) However, the infrared spectra of these fibrils contain significant
amounts of non-p-structures (1640-1680 cm-1), and this simple model cannot
account for these structures.
Figure 4.1
Model for the cross-$ fibril and FTIR obtained for synthetic $1-40. (From ref. 5)
Ao. 
Stacked
pleated sheets
14.7 6 A
Folded
polypeptide
chain
Fiber axis
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Work in our laboratory has indicated that the structure of amyloid fibrils
may be more complex than was originally suspected.1,11,1 2 The peptide p34-42
forms highly insoluble amyloid fibrils which demonstrate the cross-p fibril
diffraction pattern and are primarily P structure by as indicated by FTIR.13
However, using solid-state NMR, this peptide was shown to posess
intramolecular distances which were not consistent with antiparallel P sheets. In
particular, the Gly37-Gly38 region had very short intramolecular distances which
were consistent with a cis amide between these residues.' Using the NMR
distances as constraints, Bruce Tidor and coworkers have generated a number of
structures consistent with the NMR constraints, few of which contain idealized P
structure. This peptide also gives anomalous FTIR results when 13C labels are
introduced at various carbonyl positions.1,14 13C labelling at the carbonyl of each
amino acid would be expected to affect the amide I band in an identical manner
if the peptide is in an idealized antiparallel P sheet. However, the observed
spectra vary considerably.12 These differences can be interpreted in terms of the
local structure of the fibril; this is discussed in greater detail below. While it is
unclear whether the precise details of the structure can be extrapolated to the full
length P proteins, these results demonstrate that considerable structural diversity
can be accomodated by the data derived from X-ray diffraction and FTIR
spectroscopy.
Effect of C-Terminus on Solid-State Structure
FTIR of Unlabelled Peptides
Fibrils of the model peptides P26-39, P26-40, P26-42, and P26-43 were
prepared by adding a peptide/DMSO solution to aqueous buffer as described for
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kinetic aggregation studies in Chapter 3. After 1-2 days, the fibrils were dried on
a CaF2 plate and excess salt was removed by washing with distilled water. The
amide I band in the infrared spectra demonstrates significant structural
differences between 026-39, 026-40 and the two longer variants, p26-42 and 026-
43, which were indistinguishable by FTIR. (Figure 4.2) Each spectrum contains a
strong band at -1628-1631 cm- 1, usually ascribed to antiparallel P sheet
structure.15 However, $26-39, and to a lesser extent 026-40, contain bands
between 1640 and 1670 cm-1 indicating the presence of other structures. Bands at
1640-45 cm-1 are usually assigned as a-helix, while bands between 1660 and 1675
cm-1 are assigned as P turn or random structures. However, the assignment of
these bands is subject to some debate; in some proteins, these bands do not seem
to correlate with the amount of turn and loop structure.16
The amide I vibrational absorption band is primarily due to CO
stretching and, isolated in solution, appears at -1665 cm-1. Two effects can lead
to shifts in this band. First, changes in the hydrogen bonding environment of the
carbonyl oxygen can have small effects on the frequency of the CO stretch due to
changes in the effective mass of the oxygen. 15-17 The major contributor to shifts
in the amide I band is transition dipole coupling (TDC).15 This effect results
when two dipoles are vibrating at the same frequency, close to each other in
space, and are aligned in specific orientations with respect to each other. For two
isolated dipoles, the relationship depicted in Figure 4.3 describes the strength of
this effect. 15 This results in a rather dramatic distance dependence and a
complex angular dependence. Maximum negative band shift occurs when two
dipoles are close together and are aligned opposite each other, as depicted in
Figure 4.3. This occurs in antiparallel P sheets; every carbonyl in a strand is
rotated ~180' from the previous carbonyl. However, the angular dependence is
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Figure 4.2
FTIR spectra of the amide I band for P26-39, P26-40, P26-42 and P26-43.
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Figure 4.3
Transition Dipole Coupling
P2
AV= (1p2o 3 cos B cos y - cos ak4i / 3
not sharp, and variations of ±200 still result in significant TDC and corresponding
shifts in the amide I band. 15
The results observed for p26-39 and P26-40 suggest that the peptides
contain significant amounts of uncoupled structures. These may be due to other
secondary structures (helix, turn ?) but may also be due to simple conformational
heterogeneity, or randomness, in the peptide backbone. The sequence
differences between the highly couple peptides (P26-43 and P26-42) and the
peptides with greater disorder (P26-40 and P26-39) suggest that the C-terminus is
involved in stabilizing this conformational order. The Gly37-Gly38 region is
more conformationally flexible than the C-terminal region, which is dominated
by P branched residues.18 We thought it was likely that the extended C-terminus
was enforcing a specific structure in the Gly37-Gly38 region, while the truncated
C-termini were not rigid enough to enforce this structure. To test this
hypothesis, we synthesized 126-40 and 126-43 with 'a 13C label incorporated at
Gly37 Ca and Gly38 CO. This would allow the use of isotope-edited FTIR to
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study the local structure around Gly38, and would allow measurement of the
Gly37-Gly38 distance by rotational resonance solid-state NMR.
FTIR of Peptides Labelled at Glycine 38
Peptide fibrils were prepared from peptides 13C labelled at the G38
carbonyl. The amide I band shows differences between J26-40 and f26-43 in the
Gly38 region. In $26-43, the introduction of a 13C resulted in this band appearing
at 1614 cm-1, while the 12C band shifts from 1628 to 1635 cm-1. In P26-40, no
significant effect is observed. The 13C band does not appear below 1625 cm-1 and
the 12C band does not shift to higher wavelength. There is a slight reduction in
intensity in the region around 1665 cm-1 and a slight sharpening of the band at
1630 cm-1; this change may correspond a shift of the Gly38 13C band.
The interpretation of these results requires a discussion of the effect of
introducing a label into a transition dipole coupled network. If a 13C is
introduced into an isolated carbonyl in solution, a shift of -35 cm-1 is observed
due to the increased reduced mass of the dipole:
v = 1/27c (k / jL)1/ 2
where k is the force constant for the CO bond, and g = MC MO / (MC + MO). If a
carbonyl is involved in TDC with its neighbors (for example, in an antiparallel P
sheet, Figure 4.5), then introduction of a 13C label (boldface in Figure 4.5) will
result in disruption of this coupling, since it is vibrating at an inherently different
frequency. The result is that the 12C band which is normally observed at 1625-30
cm-1 for antiparallel p structure is shifted to 1635-45 cm-1. The observation of this
effect suggests that the region surrounding the 13C label is a highly coupled
structure. As described above, the 13C bands would normally appear at -1630
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Figure 4.4
FTIR spectra of the amide I band for P26-40 and P26-43, both labelled at Gly38.
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Figure 4.5
Idealized antiparallel 0 sheet. Bold-face C with box indicates 13C label.
0 H H
N-' C N NN NH || H || H || H
o 0 0 0
o 0 0 0
H || H || H H
'C N C KN C N N C N
1 H || H H H
0 0 0 0
eo 9 0
H |1 H " H H 11
sCN_ ' _ N' N "o'C'N N_, C_ _ N__ N-_C H HH H
o o 0 0
cm- 1, however, if they are close to each other within opposing strands of a sheet,
then the 13C carbonyls can couple with each other, resulting in this band shifting
to 1605-1620 cm- 1. As described above, the extent of this effect depends on the
distance and orientation between dipoles, thus a broad range of shifts are
observed.
The interpretation of the differences observed by isotope-edited FTIR
follows from this discussion. In f26-43 fibrils, the introduction of a 13C label
resulted in the shift of the 12C band, therefore that the VGGVV region of the
sequence is involved in TDC, and although j structure is consistent with strong
TDC, other structures can also produce this effect. The 13C band appears at
-1614 cm-1, which indicates intermediate intermolecular coupling between 13C
labels. This indicates that the labels are close together in space, but probably not
directly opposite each other, as this would result in greater TDC, and a larger
shift to -1605 cm-1. In p26-40 fibrils, the introduction of a 13C label had no effect.
The VGGVV region is probably not in a highly coupled structure. The 13C label
did not appear below 1625 cm-1, thus the Gly38 carbonyls are either not close
together in space, or they are not aligned at the proper orientations. It appears
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that some of the random structures observed at 1665 cm-1 are due to the VGGVV
region in 026-40, and introduction of the 13C label results in a shift from 1665 to
1630 cm-1, where the band overlaps with the 12C coupled band.
Gly37-Gly38 Distance Measured by Solid-State NMR
The labelled peptides described above also contained a label at Gly37
Cx, which allowed measurement of the distance between these two labels in the
solid-state. Fibrils were prepared as described above, except that 40 mg of
peptide was used in each batch. A diluted sample was also prepared: -5 parts
unlabelled peptide and 1 part labelled peptide (100 mg total) were mixed in
DMSO and aggregated in an identical manner. Finally, an unlabelled sample (50
mg) was prepared for correction of background natural abundance 13C effects.
The fibrils were collected by centrifugation and, after lyophilization, the distance
between the two labels was measured by Phil Costa, Janet Griffiths, and
Professor Robert Griffin at the National Magnet Lab using rotational-resonance
solid state NMR.
This technique is qualitatively similar to 1H NOE spectroscopy. The
100% 13C isotopically labelled Cx and CO are observed at chemical shifts which
differ by -12kHz. (Figure 4.6) Magnetization exchange requires that the sample
is spun at a rate equal to this chemical shift difference. One resonance is then
selectively inverted, and after a variable mixing time, the intensity of the other
resonance is measured. The rate of Zeeman magnetization exchange depends on
the intramolecular distance, and can be measured for distances <7 A. The
exchanged magnetization is measured at various mixing times, and this data is
compared to theoretical curves. (Figure 4.6) The result obtained is typically short
due to intermolecular exchange effects. A sample .which is diluted 5:1 with
unlabelled peptide prior to aggregation is also measured, the true intramolecular
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Figure 4.6
Rotational resonance solid-state NMR
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distance is calculated from exchange rates in this sample. The difference between
the distance measured in the 100% labelled sample and the diluted sample is an
indication of the intermolecular proximity of the 13C labels.
Table 4.1
Solid-state NMR distances for P26-40 and 126-43
peptide distance (A) dilution (% of d)
P26-43 4.05 ± 0.15 6.2%
P26-40 4.1 ± 0.1 7.3%
Table 4.1 shows the distances and dilution effects for 126-40 and P26-43.
The distance of 4.0-4.1 A between Gly37 and Gly38 requires that the intervening
amide is in the cis conformation. An idealized P sheet has a CX-CO distance of
4.74 A, and the shortest distance that can be accomodated with a trans amide is
4.4 A.1 The cis amide can be accomodated by Ca-CO distances of 4.2 A. The cis
amide had been observed previously in P34-42, and its appearance in both of
these peptides suggests that this was not an anomaly, and that Gly-Gly cis
amides may be a normal structural feature of solid-state proteins.1"1 The
dilution effect of 6-7% indicates that the labels are close together between
strands, however, dilution effects of 15-20% have been observed in other
peptides. Thus the labels are close enough to interact, but are probably not
directly across from each other. For example, the orientation of the peptide
chains in Figure 4.7 might account for these results.
Structural Model of C-Terminal Effects
The observation that 126-43 and 126-40 are similar by solid-state NMR
seems to conflict with the results obtained by isotope-edited FTIR, which
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indicated that these peptides assume different structures. However, these results
can be reconciled within a single model for the structure of 126-40 and $26-43.
$26-43 gives FTIR results which are consistent with a P sheet-like structure
similar to the structure in Figure 4.5 and Fig 4.7, however, the structure must
contain a cis amide like that in Figure 4.6. The detailed resolution of this cis
amide containing structure for 134-42 is the object of ongoing efforts in our lab in
collaboration with Bruce Tidor at the Whitehead Institute. The equation for
transition dipole coupling predicts the angular dependence of TDC is rather
broad, therefore coupling would be expected in structures which are not P sheet.
The effects observed upon inclusion of a 13C carbonyl in 126-43 would be
observed regardless of the structure, provided the criteria for local transition
dipole coupling are met.
$26-40, on the other hand, does not appear to meet the criteria for local
transition dipole coupling. The solid-state NMR data indicates that the amide
between Gly37 and Gly38 is in the cis conformation, and also indicates that the
relative orientation of the strands is similar, since similar dilution effects were
observed. Since transition dipole coupling is not observed in the viscinity of
Gly38, but the residues appear to be near each other in space, then the other
criterium for TDC must not be met: the angular dependence. Figure 4.8 shows a
Figure 4.7
Possible orientation of 126-43 peptide within the fibril.
SNKGAIIGLMVGGVVIAT
TAIVVGGVMLIIAGKNS
SNKGAIIGLMVGGVVIAT
TAIVVGGVML IIAGKNS
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Figure 4.8
Model for P26-40 with structurally heterogeneous C-termini.
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model for P26-40 in which the C-termini are disordered; the carbonyls are not
aligned in any uniform array. This would result in greatly reduced TDC and
appearance of the amide I bands at -1665 cm-1. This model may also account for
the difference in solubility observed between P26-40 and f26-43 in Chapter 3.
P26-43 is -10 fold less soluble because it is more tightly packed at its C-terminus,
while P26-40 is loosely packed. The difference in solubility would be primarily
observed in kr, as this less ordered structure would be more easily resolubilized.
A ca. 10 fold difference in kr was observed between 026-40 and P26-43 in
preliminary redissolution experiments described in Chapter 3.
Effect of Seeding on Structure of Fibrils
The C-terminal variants have dramatically different structure as
indicated by FTIR spectroscopy above. However, as described in Chapter 3, the
faster nucleating variants $26-43 and $26-42 could seed fibril formation by the
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slower aggregating variants. For instance, $26-42 could seed fibril formation by
P26-39, the kinetics are displayed in Figure 3.6. The structure of seeded $26-39
appears to be similar to the seed fibrils, $26-42. (Figure 4.9) PDMS demonstrated
that the sample contains <30% of the seed peptide, thus this spectrum is
primarily attributable to $26-39. The random structure bands observed between
1640 and 1670 cm-1 in unseeded 026-39 disappear when this peptide is seeded
with $26-42. A similar, though less dramatic effect is observed when P26-40 is
seeded with 026-43. (Figure 4.10) The random structure band is reduced in the
seeded peptide compared to the unseeded peptide. Another spectroscopic
change is the appearance of a band at -1695 cm-1, which is considered diagnostic
of antiparallel p-structure.15 These results suggest that seeding results in changes
in the structure of the amyloid fibril. Changes were also observed in the
morphology of the fibrils as discussed in Chapter 3 (Figure 3.2).
Since we had observed structural differences between $26-40 and P26-43
at Gly38 using isotope-edited FTIR, we probed whether this structural change
was taking place at Gly38. Labelled P26-40 was seeded with unlabelled $26-43
both in situ and with preformed fibrils. The spectrum was compared with
unseeded labelled f26-40 and labelled P26-43. (Figure 4.11) If the structure at
Gly38 was altered, we expected that it would become similar to the structure in
$26-43. This would result in the seeded spectrum resembling the spectrum of
labelled $26-43. (Figure 4.11 bottom) However, this was not the case; no 13C
band was observed below 1625 cm-1. The random structure observed at -1665
cm-1 in the unseeded fibril is reduced in the seeded fibril. In addition, a band
appears at 1695 cm- 1. This change upon seeding is consistent with a structural
change resulting in a more ordered, $-sheet-like structure. However, it appears
that this structure is not ordered at Gly38. Thus it seems that seeding provides a
template which is capable of altering the structure of the peptide as it aggregates,
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Figure 4.9
FTIR of amide I band for P26-39 seeded with P26-42.
$2639
$2639 seeded
with$2642
02642
1700 1650 1600
Wavenumbers (cm1)
Figure 4.10
FIR of amide I band for P26-40 seeded with $26-43.
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Figure 4.11
FTIR of amide I band for G38 labelled P26-40 seeded with P26-43.
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however, this template effect is not perfect: it does not result in the identical
structure in the seed and seeded peptides.
Factors Which Affect Cis Amide Equilibrium in Solution
As a result of the experiments described in Chapters 3 and 4 of this
thesis, a complete model for the mechanism of P protein amyloid formation has
to explain the following observations:
1. The cis amide appears to be a common solid-state feature of all of the
protein amyloids studied. Either this is a very stable structure in the solid
state, and/or trans -> cis isomerization is an integral step in the fibril
formation pathway.
2. The longer variants (P26-43 and P26-42) nucleate much more rapidly than the
shorter variants ($26-40 and P26-39). This may be due to a faster kf, larger Kn,
or an increased concentration of the aggregating species.
3. Despite the fact that both P26-43 and $26-40 contain a cis amide, $26-43 is
more ordered than P26-40 in the region surrounding Gly38.
It is difficult to imagine why the formation of a cis amide would be an integral
step in the aggregation pathway, since both the cis and trans isomers are equally
hydrophobic. However, our results have indicated that the structure of the fibril
plays a more important role than the hydrophobicity of the monomer in
determining the solubility of a peptide. In particular, if the cis amide containing
isomer is able to form a more structured and stable nucleus, then changes in the
population of the cis isomer might affect nucleation kinetics. We suspected that
the extended C-terminus of the longer variants might result in increased
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population of the cis isomer in solution. Factors which could contribute to this
effect are discussed below.
The cis amide is usually present at a very small concentration in
solution. For instance, calculations predict that in the dipeptide Ala-Ala, the cis
isomer will be only 0.1% of the equilibrium population.19 However, in Gly-Gly,
some of the steric hindrance due to side-chain interaction in the cis isomer is
relieved, and the population of the cis isomer may be as high as 1.5-2%.20
Typically, the cis amide is observed in solution by NMR techniques. For
instance, natural abundance 13C NMR was used by Wuthrich and coworkers to
observe the cis/trans ratio in short proline containing peptides. 21 The lifetime of
the cis isomer is on the order of 10 sec, and therefore cis and trans isomers should
give two distinct sets of resonances on the NMR time scale. 22,23 The model
peptides which were studied throughout Chapters 3 and 4 are relatively
insoluble in aqueous media (Cs<10 kM, solutions of >500 p.M aggregate
immediately), and thus are not amenable to this type of analysis. We attempted
to observe the cis isomer in aqueous solution for the short model peptide $36-39
(Ac-VGGV-NH2) which is soluble at -5 mM, but we were unable to detect
separate resonances, implying that the amount of cis isomer is probably less than
2%. (Figure 4.12A) However, in DMSO, two sets of resonances were detected for
Gly aH and for certain amide protons.(Figure 4.12B) These resonances may be
the cis isomer, in which case, the cis isomer is -5% in DMSO.
The amount of cis isomer in aqueous solution is not enough to detect by
1H NMR. All other systems which had been studied by this method usually
contained proline, resulting in a cis amide population of 10-30%.21 This higher
population is due to the steric interactions of proline 8CH 2 and XCH with the
neighboring carbonyl, which are relatively equal. Though both cis and trans
isomers are sterically hindered, they are populated to nearly equal degrees. If
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Figure 4.12
NMR of P36-39 (Ac-VGGV-CONH2, Ha only) in (A) buffered D2 0 and (B)
DMSO.
A. D20 B. DMSO
trans
cis ?
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one assumes that this local interaction is separable from surrounding sequence-
dependent effects, 24 then any thermodynamic effects which would alter the
population of a cis proline amide would also alter the population of a cis amide
between other residues to a similar extent. In our system, we could introduce a
proline in place of Gly38 and measure the resulting cis/trans equilibrium, which
would be on the order of 30%. If a particular surrounding sequence increased
the cis isomer to 40%, then based on the previous assumption, we could predict
that the same change would increase the population of the cis amide in the Gly-
Gly containing peptide from 1.5% to 2.0%. In order to simplify assignment of the
spectrum, we decided to use sarcosine instead of proline; this provides two sharp
singlets in the 1H NMR which can be integrated to provide an accurate measure
of Kc/t. (Figure 4.13)
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Figure 4.13
N-Methyl group in sarcosine provides an NMR probe for Kc/t.
N H2
0 CH y/T O
N N H2j NC3
0 H 0
To provide a baseline for estimating the sequence stabilization effect, we
measured the cis/trans ratio in Ac-Gly-Sar-NH2, which we assumed had no
intramolecular stabilization in solution. This peptide was 22.8% cis in solution
(Kc/t = 0.296). (All results are reported in D20, 100 mM NaCl, 10 mM phosphate,
pD 7.0, T=250C) A series of peptides were studied corresponding to P36-39 and
P35-40, and one model peptide, Ac-AGSarA-NH 2; the methyl resonances for
three sample spectra displayed in Figure 4.14, and the results are summarized in
Table 4.2. (complete spectra are displayed in the Appendix) The addition of a
single alanine to each side of the Gly-Gly region did not stabilize the cis amide on
its own, however addition of valine resulted in 2.3% more cis amide in solution.
Addition of another residue on each side resulted a slight increase of 1.2%.
Changing the C-terminal amide to an anionic carboxylate (at pH 7) resulted in
1.1% more cis amide. The error in these measurements was estimated by
repeating the measurement and integration ten times on Ac-VGSarV-NH2, and
calculating the standard deviation of the results. This error was very small
(±0.2%) and indicates that the the increases measured are not due to
experimental fluctuations.
We suspected that this increase was due to intramolecular interactions
between the opposite ends of each peptide. While addition of alanine resulted in
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Figure 4.14
The N-methyl amide singlets for the cis and trans peptides in aqueous buffer.
Spectral region displayed is 2.6-3.2 ppm.
Ac-MVGGVV-CONH 2 Ac-VGGV-CONH 2 Ac-GG-CONH 2
no stabilization of the cis amide, addition of valine resulted in a significant
increase in the population of the cis amide. This suggests that the interactions
which are stabilizing the cis amide are not hydrogen bonds, as these would have
been similar in AGSarA and VGSarV. Instead, we propose that hydrophobic
interactions between the valine side-chains are stabilizing a conformation which
contains the cis amide. Since hydrophobic interactions are increased at higher
temperature, we measured the population of the cis amide in
Ac-MVGSarVV-CO 2H at three temperatures. (Table 4.3) The cis amide is
Table 4.2
Cis/trans equilibrium for model peptides in aqueous buffer.
relatively more stable
hydrophobic effects.
at high temperature, supporting the
The temperature dependence of
involvement of
this cis/trans
isomerization allows calculation of the AH0 and ASO for this specific peptide:
AH0 (T->C) = +0.336 kcal mol-1, and AS(T->C) = -7.94 x 10-4 kcal mol-1 K-1. The
high enthalpic difference between trans and cis isomers is due primarily to steric
hindrance in the cis isomer. The entropy was found to decrease on conversion
from the trans to the cis isomer. This suggests that the cis isomer is more ordered
than the trans isomer, consistent with a model in which the peptide chain is
constrained by hydrophobic collapse to a turn-like structure. The entropic
change of this "folding" and isomerization is -0.13 cal K-1 mol-1 residue-1, which
is much smaller than values measured for the complete folding of small proteins
(for instance, -3.2 cal K-1 mol-1 residue-1 for BPTI25) thus it is likely that this
stabilized cis containing structure still has a great deal of conformational
flexibility.
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peptide trans cis Kc/t AG A(AG)
(%) (%) (kcal/mol) (kcal/mol)
Ac-GSar-NH2 77.2 22.8 0.296 0.723
Ac-AGSarA-NH2 77.0 23.0 0.298 0.719 -0.005
Ac-VGSarV-NH2 74.7 25.3 0.338 0.644 -0.079
Ac-MVGSarVV-NH2 73.5 26.5 0.360 0.607 -0.117
Ac-MVGSarVV-CO2H 72.4 27.6 0.381 0.573 -0.150
error ±0.2 ±0.2 ±0.003 ±0.006 ±0.009
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Table 4.3
Temperature dependence of cis/trans equilibrium for Ac-MVGSarVV-CO 2H.
Temp trans cis Kc/t AG
C(%) (%) (kcal/mol)
11 73.0 27.0 0.370 0.565
25 72.4 27.6 0.381 0.573
45 71.7 28.3 0.395 0.591
AG = AH - TAS
AH = 0.336 kcal mol-1
AS = 7.94 x 10-4 kcal mol-1 K-1
The prevalence of cis-proline in turn structures has long been
recognized.18  Pauling calculated that cyclic structures would result in
stabilization of cis amides, the most dramatic of these is the cyclic dipeptide or
diketopiperazine, which occurs only in the cis conformation. 26 A cis amide has
also been observed in a cyclic hexapeptide (6% cis) 27 and in a peptide which
contains an i, i+1 Cys-Cys disulfide (70% cis). 28 Factors which stabilize turn
structures in short proline containing model peptides also increase the
population of the cis amide structure.21,29 However, none of these papers has
referred to hydrophobic factors stabilizing the cis amide. Kelly and coworkers
have explored hydrophobic stabilization of turns as factors which might be
involved in initiating protein folding.30-32 Using p-turn templates to increase the
population of the turn structure in solution, they find that the hydrophobicity of
residues i and i+4 within the turn, and i-2 and i+6 outside the turn are critical in
stabilizing nascent structure. This structure is not a true P structure, but is best
described as a hydrophobic cluster which enforces a'transient 1-like structure in
solution.30 A similar hydrophobic cluster has been proposed as a structural
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nucleus in the urea-denatured molten globule. 32 We propose that an
intramolecular hydrophobic cluster may result in the formation of a turn
structure centered around Gly37-Gly38. In such a turn structure, the cis amide
may be stabilized relative to the trans amide, analogous to the case in a proline
turn. A model for the role of this effect in P protein aggregation is discussed
below.
The assignment of the minor isomer as the cis isomer in the model
peptides above was confirmed using NOE spectroscopy. In the extended
conformation, the N-methyl trans isomer is expected to have an NOE with each
of the neighboring Hus, while the cis isomer is expected to have an only a weak
NOE with the intraresidue Ha and no NOE with the i-1 Ha. (Figure 4.15) By
analogy with proline containing peptides, a qualitatively similar result is
expected for all other possible conformations. 33 In the 2D NOESY spectrum, two
negative NOEs are observed between the N-methyl peak of the major isomer and
the Ha region, while only a weak NOE is observed for the minor isomer. (Figure
4.16) Using 1D NOE difference spectroscopy, irradiation on the major methyl
resonance results in two negative NOEs in the Ha region, while irradiation of the
minor isomer results in only a single weak NOE which is nearly hidden by the
baseline noise. (Figure 4.17) Interestingly, a positive NOE is observed for
chemical exchange processes, thus a strong positive peak is observed for the
minor isomer when the major isomer is irradiated. The t1/2 for this process is on
the order of these NMR experiments, -1-10 sec. The proper method for
measuring this interconversion is by the inversion-transfer method.23 One
resonance is selectively inverted, and after a variable mixing time, the intensity of
the other resonance is detected. Using this method, the rate of isomerization of
trans to cis isomerization for Gly-Pro is estimated to be 5 x 10-3 sec-1, resulting in
t1/2 for trans to cis isomerization on the order of 100 sec. 34
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Figure 4.15
Expected NOEs for cis and trans Ac-Gly-Sar-NH2
Minor Isomer - 1 weak NOE - cis N-methyl amide
0
NH2
H N ) 0
0OCH 3
Major isomer - 2 strong NOEs - trans N-methyl amide
0 CH3  0
N NH2H 0
Figure 4.16
NOESY spectroscopy of Ac-Gly-Sar-NH2.
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Figure 4.17
NOE difference spectra of Ac-Gly-Sar-NH2-
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Model for C-Terminal Effects on Kinetics and Structure
As stated earlier, any model which hopes to explain the molecular
details of amyloid formation from the @ proteins must explain (i) the prevalence
of the Gly-Gly cis amide in the solid state, and (ii) the faster nucleation of the 43
and 42 residue forms as compared to the 40 and 39 residue forms. I propose a
model which is based upon the principles of protein folding. In solution, each
monomer is in equilibrium between a large number of extended forms and also a
number of collapsed forms, which are stabilized since they bury a small amount
of hydrophobic surface area which would otherwise be exposed to water.35
These collapsed forms are similar to the molten globule in protein folding: they
are mostly unstructured, yet may contain small amounts of transient structure
which may act as a nucleus for structure formation.31,32 The Gly37-Gly38 region
may initially act as an extremely flexible hinge which allows the hydrophobic
side-chains of the residues surrounding this hinge to collapse together. (Figure
4.18) The cis isomer may be favored in this collapsed U-shaped structure, similar
to the way cis proline is favored in turns. 29 On the other hand, the cis amide
isomerizes much slower than the other rotational motion in a peptide chain, this
may prevent the breathing which otherwise occurs in molten globules.32 The
hydrophobic effects thermodynamically stabilize the cis amide, and the cis amide
kinetically stabilizes the turn structure.
The extended trans structures are highly flexible, thus aggregation must
overcome the entropy which is inherent in a flexible chain, as well as the entropy
due to translational and rotational freedom. 36 Thus the disfavorable entropic
change upon forming a nucleus from extended structures is large, since this
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Figure 4.18
Model for role of cis/trans isomerization in nucleation of the P proteins
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flexibility is contrained in the structured nucleus. However, the collapsed cis
structures are already partially constrained, since some of the chain
flexibility is lost upon formation of a hydrophobically stabilized turn structure.
Thus, nucleation only needs to overcome the entropy due to translational and
rotational motion. This effect will increase the forward rate, kf, for nucleation,
(see Chapter 2) and therefore also increase Kn and possibly Kg. If one assumes a
rate-limited model for aggregation and a 10mer nucleus, as was discussed in
Chapter 2, then a 10% increase in kf results in a decrease in the delay time of 2.4
fold (1.110). On top of this effect, we have already demonstrated that the
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concentration of the cis isomer is increased due to hydrophobic collapse. For
instance, if the cis amide is normally 1.5% in solution, then in P26-40 the cis
amide would be -1.8%, and in p26-42 may be much higher, due to increased
hydrophobic interactions. Since the delay time is related to Cn, this might result
in a 7-14 fold decrease in delay time. Together these two effects could account
for the decrease in delay time observed in our model studies. After nucleation
occurs, then the fibrils can grow using any of the P protein variants. (Figure 4.18)
A combination of this structural model for nucleation with the model for
amyloid formation dicussed at the end of chapter 3 may be able to explain
amyloid formation in AD. In diseased individuals, a mutation or errant
proteolysis results in formation of p1-42 or 1-43 instead of the normal product,
P1-40. A hydrophobic collapse around the flexible GlyGly hinge, accompanied
by trans to cis isomerization, conformationally restricts the otherwise flexible
peptide chain. The entropic factors which normally oppose nucleus formation
are now less important, and nucleation rapidly occurs. Fibril growth can now be
sustained at low concentration using any of the P proteins, resulting in steady
growth of amyloid plaques.
Experimental
Peptide Synthesis
Unlabelled peptides were synthesized and purified as described in
Chapter 3. 126-40 and 126-43 labelled at Gly37 (Ca) and Gly38 (CO) were
synthesized and purified according to the same procedure, except that labelled
Boc-Gly was substituted at the appropriate positions. Labelled glycine (>99%
13C, Cambridge Isotope Labs) was protected using the BOC-ON reagent
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according to a published procedure. 37 The product was isolated by extraction
into ethyl acetate, dried in vacuo, and the resulting clear oil was dissolved in DMF
and used in coupling reactions without further purification or characterization.
After cleavage and purification as described in Chapter 3, the peptide was
characterized by mass spectrometry and by 13C solid-state NMR. Mass
spectrometry indicated a single parent ion corresponding to M+H+. p26-40:
1460.4 (calculated 1459.8). 02643: 1746.2 (1745.1). Minor amounts (<5 %) of an
impurity corresponding to ~M+95 were detected in some batches of each
peptide. This impurity was degraded upon exposure to 1 M NaOH/DMSO (1:1),
indicating alkylation of methionine was probably responsible. 38 Increases in
thiol scavengers and/or decreases in the length of deprotection may reduce these
impurities in the future.
Peptides containing N-methyl amides for solution NMR studies were
synthesized using standard Fmoc peptide chemistry and the Rink amide MBHA
resin (0.5 mmol/g, Novabiochem). Couplings were achieved with Fmoc-amino
acid (3 eq), BOP (3 eq), and DIEA (6 eq) in DMF (5 ml/g), gently agitated for 30
min, folowed by washing the resin with DMF. The Fmoc protecting group was
removed with piperidine/DMF (1:1) for 10 min, followed by washing the resin
with DMF. Fmoc-sarcosine (N-methyl glycine) was introduced in the same
manner. The residue following sarcosine (Fmoc-glycine) was introduced by
substituting the more reactive PyBroP for BOP, and extending the coupling time
to 2 hrs. The N-terminus was acetylated with Ac2O (5 eq) and DIEA (5 eq) in
CH 2Cl2 for 2 hrs, followed by washing with CH 2Cl 2. The peptide was removed
from the resin by stirring with neat TFA at room temperature for 15 min. The
resin was filtered and the supernatant was concentrated to an oil. The oil was
dissolved in H20 and lyophilized. The crude peptide was dissolved in DMSO
and purified by RPHPLC. (C4 prep, 80 ml/min, linear gradient from 95/5 to
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65/35 H20/CH3CN (0.1% TFA) over 15 min, peptides typically eluted as a sharp
peak at 8-10 min, except Ac-Gly-Sar-NH2, which eluted just following the solvent
peak) The eluents were lyophilized, providing the pure product as a white solid,
except for Ac-Gly-Sar-NH2, which was obtained as an oil. Purity and identity
were verified by analysis of the NMR spectra recorded in DMSO (See Appendix
for spectra).
NMR (DMSO, 500 MHz):
Ac-VGGV-NH 2 : 6 8.27(t, 1H, J=5 Hz, G NH), 8.01(t, 1H, J=6, G NH), 7.92(d, 1H,
J=8.5, V NH), 7.71(d, 1H, J=9.5, V NH), 7.37(s, 1H, C-term. NH2), 7.03(s, 1H, C-
term. NH 2 ), 4.09(m, 2H, A aH), 3.75(d, J=5.5, 2H, G xH), 3.70(m, 2H, G aH),
1.95(m, 2H, V PH), 1.83(s, 3H, acetyl), 0.84(m, 12H, V WCH3).
Ac-GSar-NH2: 6 7.93(d, 1H, J=5 Hz, G NH), 7.51(s, 0.4H, cis C-term. NH2 ), 7.30(s,
0.6H, trans C-term. NH 2 ), 7.20(s, 0.4H, cis C-term. NH 2), 7.05(s, 0.6H, trans C-
term. NH2 ), 3.95(d, 1.2H, trans G LH), 3.91(s, 0.8H, cis Sar xH), 3.84(s, 1.2H, trans
Sar xH), 3.80(d, 0.8H, J=5.5, cis G aH), 2.94(s, 1.7H, trans Sar CH 3), 2.78(s, 1.3H,
cis Sar CH 3 ), 1.85(s, 1.7H, trans acetyl), 1.84(s, 1.3H, cis acetyl).
Ac-AGSarA-NH 2 : 8 8.23(d, 0.4H, J=7 Hz, cis A NH), 8.07(d, 1H, J=8, A NH),
8.01(d, 0.6H, J=7.5, trans A NH), 7.83(m, 1H, Gly NH), 7.40(s, 0.4H, cis C-term.
NH 2), 7.27(s, 0.6H, trans C-term. NH 2), 7.01(s, 0.4H, cis C-term. NH 2), 6.99(s,
0.6H, trans C-term. NH 2 ), 4.30(m, 0.8H, J=8, A aH), 4.20(m, 0.8H, J=7.5, A xH),
4.01-3.79(m, 4H, G & Sar aH), 2.94(s, 1.4H, trans Sar CH 3 ), 2.77(s, 1.2H, cis Sar
CH 3), 1.82(s, 3H, acetyl), 1.18(m, 6H, A fCH 3).
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Ac-VGSarV-NH2: 8 8.06(d, O.4H, J=8.5 Hz, cis V NH), 7.96(t, 0.5H, J=5.5, G NH),
7.92(t, 0.5H, J=5.5, G NH), 7.88(m, 1H), 7.82(d, 1H, J=9, V NH), 7.46(s, O.4H, cis C-
term. NH 2 ), 7.38(s, 0.6H, trans C-term. NH 2), 7.06(s, O.4H, cis C-term. NH 2 ),
7.03(s, 0.6H, trans C-term. NH 2 ), 4.2-3.8(m, aH), 2.94(s, 1.6H, trans Sar CH 3),
2.77(s, 1.4H, cis Sar CH 3 ), 1.95(m, 2H, V PH), 1.85(s, 3H, acetyl), 0.85-0.78(m, 12H,
V TCH 3 ).
Ac-MVGSarVV-NH 2 : 6 8.17(d, O.4H, J=8.5 Hz, V NH), 8.07(d, 0.7H, J=8.5, V NH),
8.02-7.68(m, 3.5H, NH), 7.33(s, 0.5H, C-term. NH 2), 7.31(s, 0.5H, C-term. NH 2 ),
7.01(s, 1H, C-term. NH 2), 4.2-3.9(m, 8H, aH), 2.92(s, 1.5H, trans Sar CH 3 ), 2.76(s,
1.5H, cis Sar CH 3 ), 2.42(m, 2H, M -CH 2 ), 2.01(s, 3H, M ECH 3), 2.03-1.70(m, 5H, V
& M $H), 1.83(s, 3H, acetyl), 0.90-0.75(m, 18H, V yCH3).
Ac-MVGSarVV-OH: 6 8.14(d, 0.5H, J=8.5 Hz, V NH), 8.08(d, 1.4H, J=8, V NH),
7.99(m, 1.6H, NH), 7.89(d, 0.5H, J=8.5), 7.74(t, 1H, J=8.5), 4.4-3.8(m, 8H, xH),
2.92(s, 1.6H, trans Sar CH 3), 2.76(s, 1.4H, cis Sar CH 3), 2.44(m, 2H, M CH 2),
2.02(s, 3H, M ECH 3), 2.07-1.72(m, 5H, V & M PH), 1.83(s, 3H, acetyl), 0.89-0.81(m,
18H, V CH 3).
NMR (D2O, 100 mM NaCl, 10 mM phosphate, pD 7,500 MHz):
Ac-VGGV-NH 2 : 6 4.00(d, 1H, J=7 Hz, V xH), 3.97(d, 1H, J=6.5, V caH), 3.87(d, 1H,
JG=17, G aH), 3.86(s, 2H, G aH), 3.82(d, 1H, JG=17, G aH), 1.98(m, 2H, J=7, V
PH), 1.93(s, 3H, acetyl), 0.85-0.80(m, 12H, V ICH3).
Ac-GSar-NH 2 : 6 4.07(s, 0.4H, cis Sar xH), 4.05(s, 1.5H, trans Sar xH), 3.98(s, 1.5H,
trans G caH), 3.92(s, 0.5H, cis G aH), 2.99(s, 2.3H, trans Sar CH 3), 2.83(s, 0.7H, cis
Sar CH 3), 1.94(s, 2.3H, trans acetyl), 1.93(s, 0.7H, cis acetyl).
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Ac-AGSarA-NH2: 8 4.20(m, 1.6H, J=7.5 Hz), 4.11(s, 0.4H, G aH), 4.05-3.90(m,
3H), 2.98(s, 2H, trans Sar CH 3), 2.80(s, 0.7H, cis Sar CH 3), 1.90(s, 3H, acetyl),
1.27(m, 6H, A $CH 3).
Ac-VGSarV-NH2: 8 4.16(d, O.4H, J=3.5 Hz, V aH), 4.1-4.0(m, 4H, uH), 3.92(d,
0.6H, J=5.5, V aH), 2.98(s, 2H, trans Sar CH 3), 2.80(s, 1H, cis Sar CH 3), 1.98(m,
2H, V PH), 1.94(s, 3H, acetyl), 0.87-0.80(m, 12H, V yCH 3).
Ac-MVGSarVV-NH 2: 8 4.34(m, O.7H, cH), 4.1-3.9(m, 6.6H, aH), 2.98(s, 2.3H,
trans Sar CH 3), 2.81(s, 0.7H, cis Sar CH 3), 2.47(m, 2H, M ICH2), 1.99(s, 3H, M
ECH 3), 2.03-1.83(m, 5.6H, V & M PH), 1.92(s, 3H, acetyl), 0.90-0.80(m, 18H, V
yCH 3).
Ac-MVGSarVV-OH: 8 4.33(t, 0.6H, J=7.5 Hz, M 6H), 4.15-3.9(m, 7H, LH), 2.97(s,
2.4H, trans Sar CH 3), 2.81(s, 0.9H, cis Sar CH 3), 2.45(m, 2H, M NCH 2), 1.98(s, 3H,
M ECH 3), 2.03-1.85(m, 5H, V & M PH), 1.91(s, 3H, acetyl), 0.85-0.75(m, 18H, V
)CH 3).
FTIR spectroscopy
Peptide fibrils were prepared as described in Chapter 3 for kinetic
aggregation studies. Seeded fibrils were prepared using both the fibril and in situ
seeding method; similar results were obtained. The fibrils were collected by
centrifugation and suspended in a minimal amount of H 20. A small amount of
this suspension (-50-100 p1) was spread on a clean CaF2 plate, and dried in vacuo.
The resulting film had noticeable salt crystals encrusted on top, these were
removed by gently dipping the plate in distilled H20. Alternatively, a few drops
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of water were layered on top of the film and the resulting salt solution wicked
away with a Kimwipe. This procedure was repeated 2-3 times to ensure
complete removal of excess salt. Failure to remove the salt resulted in noisy
spectra due to water bound to the salt crystals. The resulting peptide film was
dried in vacuo for at least 24 hr. Spectra were recorded on a Perkin-Elmer 1600
series Fourier-transform infrared spectrophotometer. Sixteen scans were
averaged with 2 cm-1 digital resolution. Contribution from residual water vapor
in the air was manually subtracted. Spectra were smoothed with 10 cm-1
bandwidth smoothing functions. Figures contain spectra that were normalized
such that the maximum absorbance in the amide I band was 1.00. Peak positions
were determined with the aid of second derivative analysis. Plates were cleaned
prior to use by dipping in neat TFA followed by rinsing with copious amounts of
water.
Solid-State NMR Spectroscopy
Solid-state 13C NMR spectra were recorded by Phil Costa in the
laboratory of Professor Robert Griffin at the National Magent Lab. Typically 40-
80 mgs of aggregated peptide labelled at Gly37 Cax and Gly38 CO was prepared
according to the method described in Chapter 3 for kinetic aggregation studies.
The peptide was collected by centrifugation and lyophilized. Generally, the
spectrum of the labelled peptide (-30-40 mg) is recorded and the chemical shift
difference between the labelled resonances is determined. Rotational resonance
occurs when the spin rate is equal to this value, typically -12000 Hz. Under
these conditions, magnetization is transferred from one nucleus to the other at a
rate that is a function of the distance between the nuclei. One resonance is
selectively inverted, and after a short mixing time, the intensity of the other
resonance is measured. A comparison of this data to model exchange curves
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yields a distance to within ±0.1 A. However, interstrand exchange may occur if
the labelled residues are near each other in opposing strands within each sheet.
In order to correct for this possible effect, a sample (-80 mg) is prepared in an
identical manner with the label diluted with unlabelled peptide (-1:5). Analysis
of this peptide requires subtraction of the contribution from the overlapping
natural abundance spectrum. Analysis of the diluted data yields a true
intrastrand distance which may be as much 20% longer than the distance
measured in the fully labelled sample. This dilution effect is an indication of
interstrand proximity of the labelled residues.
Solution NMR Spectroscopy
Peptide models for the Gly-Gly cis/trans equilibrium were studied by
solution 1H NMR spectroscopy. Peptide identity and purity was initially
confirmed by recording NMR spectra at 500 MHz in DMSO (Temp = 25'C, 64
transients averaged). (See appendix for complete spectra) NMR spectra were
collected in buffered D20 at 500 MHz. Buffer was prepared initially in H20 (100
mM NaCl, 10 mM NaH2PO 4, pH adjusted to 7.4 with 1 M NaOH), and then
lyophilized and dissolved in an equal volume of D20. This procedure was
repeated two times; the pD (uncorrected) was 7.0. Lyophilized peptide (3.0 mg)
was dissolved in 1.5 ml of buffer and filtered (0.22 tm syringe filter) into a clean
NMR tube. In the case of the Ac-MVGGVV peptides, the peptide was not soluble
at this concentration. These samples were sonicated for 5-10 min, centrifuged
and filtered, and diluted with 200 [1 of buffer. Spectra were recorded at 25'C
unless otherwise stated, each spectrum is an average of 128 transients. The
sweepwidth of the spectrometer was set to include only the 0-5 ppm region of
the proton spectrum. The cis and trans methyl amide resonances were
integrated; integration cuts were set manually. Repeated integration of the same
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sample indicates that the error is - ±0.4% of the measured integration. Extreme
care was required to ensure proper shimming of the instrument. Improper
shimming resulted in split singlets and/or loss of peak intensity due to
broadening. Typically, the shimming process required initial adjustment of Z1
through Z5 shims with sample spinning, followed by adjustment of the
nonspinning shims (XY, XZ, and YZ) with a stationary sample, both using the
lock intensity as the criterium, and finally, careful adjustment of Z1 through Z5
shims using the HDO resonance lineshape and width as criteria, with the sample
spinning. In general, on the VXR-501 spectrometer, the width of the HDO peak
could be reduced to -0.3-0.5 Hz (FWHM), although Lorentzian lineshape was
much more important than resolution.
The trans methyl amide was identified in Ac-Glycine-Sarcosine-NH2 by
two methods, NOE difference spectroscopy and NOESY spectroscopy. The
sample was shimmed as described above. The T1 relaxation times for the methyl
amides were measured by the inversion-recovery method, and were both -0.6
sec at 25*C. In the NOE difference method, with the sample spinning, one
resonance was saturated by selective irradiation for 3xT1, a 900 pulse (42.5 sec)
was applied, and the FID was recorded for 3xT1. The decoupler was arrayed
with a second offset set to a nearby region of the spectrum where no resonances
were observed (-2.7 ppm), and the decoupler power was set to 35. 1024
transients were recorded using interleave with a block size of 16. The averaged
FIDs for the on-resonance and off-resonance spectra were subtracted, and
transformed using zero-filling and Gaussian weighting to reduce noise. In the
NOESY method, more careful shimming in the XY dimension with the sample
stationary resulted in a symmetric HDO peak with a linewidth of 1.5 Hz
(FWHM, nonspinning). A data matrix was collected that was 1024 FIDs in the T1
dimension (32 transients each) x 512 increments in the T2 dimension. The
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spectra were recorded at 30*C. A mixing time of 200 msec was used (in a
previous experiment, 100 msec gave no detectable NOEs). The data was zero
filled to 2048 points in T1 and T2, and transformed using gaussian weighting and
positive line broadening. After transforming, the data was phased in both
dimensions using slices through the isolated diagonal peaks of the acetyl and Gly
Cc singlets. The baseline was corrected using a spline (linear) correction
algorithm. The T1 noise was still considerable relative to the weak intensity of
the observed NOEs. However, since small peptides give rise to negative NOEs
for through space magnetization transfer, and T1 noise is primarily positive, then
the NOEs could be extracted by plotting only negative cross peaks.
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